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The cryptophycin family of cyanobacterial peptolides contains 
exceptionally potent antimitotic anticancer agents. Active at levels 
significantly lower than currently approved cancer therapies, synthetic 
cryptophycin 52 was also effective against multi-drug resistant cancers. 
Phase II clinical trials revealed minor peripheral neurotoxicity, however, 
making synthetic derivatization a priority for the development of safe, 
effective cryptophycins for the treatment of cancer. Specifically, incorporation 
of heterocycles on unit A of cryptophycin was proposed to increase the 
solubility and stability, as well as reduce toxicity of the parent drugs. To this 
end, an efficient and divergent synthetic route to unit A analogues was 
developed and optimized for the production of a diverse library of heterocyclic 
functionality. Incorporation with units B, C, and D yielded fully elaborated, 
SNAc-thioester bound seco-cryptophycins as substrates for macrocyclization. 
Cryptophycin thioesterase (CrpTE) activity was reconstituted in vitro and used 
to demonstrate impressive inherent flexibility for a suite of heterocyclic 
substrates. CrpTE was then optimized for activity and displayed little 
preference for reaction temperature, buffer pH, or DMSO concentration. 
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Incredibly, CrpTE was active at up to 50% DMSO and in a variety of organic 
solvents. In fact, a novel cosolvent system of 20% diglyme with 1% MCD 
more than doubled CrpTE conversion with a natural substrate mimic and 
proved to be an effective strategy for the chemoenzymatic cyclization of the 
2-pyridyl derivatized cryptophycin 500. Joined with the complementary 
heterocyclic substrate flexibility of cryptophycin epoxidase (CrpE), a powerful 
method now exists to produce unique cryptophycins in a campaign to access 
better anticancer agents. This chemoenzymatic method should also provide a 
means to construct affinity probes for mechanism of action studies and 






1.1 CANCER CHEMOTHERAPY AND ANTIMITOTIC AGENTS 
In November 1947, Dr. Sidney Farber quietly ushered in the age of 
cancer chemotherapy. Leading up to his discovery, Dr. Farber was a pediatric 
pathologist at Harvard and Children’s Medical Center, where he saw many 
samples from children with what was then terminal cancer.1 His studies on 
these samples revealed that folic acid stimulated leukemic cell growth and 
enhanced disease progression, and he therefore reasoned that folic acid 
antagonists would inhibit the proliferation of these cancer cells.2 Coincident 
with these observations, researchers at Lederle Laboratories synthesized a 
series of folate metabolism inhibitors (antifols) and demonstrated that they 
inhibited the growth of normal cells.3 Farber took notice and requested a 
small amount of 4 antifols (pteroylaspartic acid, pteroyl diglutamic acid, 
pteroyl triglutamic acid and 4-aminopteroyl glutamic acid (aminopterin)), 
which were administered to 16 children with acute undifferentiated leukemia. 
The resulting temporary remissions, with clinical, hematological, and 
pathological improvement in 10 children, many of whom were terminal at the 
time therapy was initiated, represented the first successful clinical use of 
cancer chemotherapy.4 
  Much has changed in the battle against cancer over the past 65 
years, and anticancer drugs now cover dozens of mechanisms of action. 
However, drugs that interfere with microtubule dynamics have been a 
particularly successful class. Microtubules (MTs) are cytoskeletal polymers 
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Figure 1.2: Structures of microtubule-stabilizing and destabilizing agents. 
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organized in microtubule organizing centers (MTOCs), such as the 
centrosome or the basal bodies in cilia and flagella. Contained within the 
MTOC is γ-tubulin, which, together with associated scaffold proteins, forms 
the γ-tubulin ring complex.5 This complex acts as a scaffold for α/β-tubulin 
dimers to begin polymerization. MTs are also involved in cell division through 
the formation of mitotic spindles, which separate chromatids or genomic DNA 
during cell division. In addition, there are many proteins that bind to MTs, 
including motor proteins such as kinesin and dynein, and other proteins 
regulating microtubule dynamics.6 Their dynamic instability can be described 
by the parameters of growth, shrinkage, and rates of catastrophe and rescue 
(Figure 1.1),7,8 which are controlled by the interaction of α- and β-tubulin 
dimers and fueled by the hydrolysis of GTP.9,10 MT-targeting drugs interrupt 
this polymer flexibility and cause affected cells to arrest at the G2/M phase of 
mitosis and undergo apoptosis.11  
Drugs that interact with MTs are structurally diverse (Figure 1.2), but 
can be classified into two main groups: stabilizing agents, which promote 
polymerization and stabilize the MT polymer, and destabilizing agents, which 
promote depolymerization and prevent rescue. The majority of these 
compounds are natural products or synthetic derivatives of natural products,  
 
Figure 1.2: Model of the tubulin heterodimer (α in purple and β in gray) in complex with 
colchicine (purple) and GTP/GDP (yellow). The taxoid site is indicated in green and the “peptide” 




and most likely evolved as broad-spectrum toxins to eukaryotic predators. MT 
stabilizers bind to either one of the tubulin subunits (Figure 1.3) in one of two 
well-known binding sites: the taxoid site or the not yet fully characterized LAU 
site named for laulimalide.11 Both of these sites are located externally on the 
β-tubulin subunit and are typically occupied in a 1:1 stoichiometry of one drug 
molecule per one heterodimer. MT destabilizers also have binding sites on 
the exterior of the heterodimer with a preference for the β-tubulin subunit. The 
vinca alkaloids are the most recognized of the destabilizers, and bind on the 
surface of β-tubulin overlapping the “peptide” binding site near the interface 
of two heterodimers.13 Interestingly, destabilizers have been indicated to bind 
to microtubules in a far larger ratio of heterodimers to drug molecules. 
Included in the MT-stabilizer category is another class of anticancer natural 
products, the cryptophycins, which are the topic of this dissertation and will 
be discussed in detail in the next section.  
  
1.2 THE CRYPTOPHYCINS 
 The cryptophycins and the closely related arenastatins are a family of 
lichen-derived cyanobacterial peptolides and are biosynthetically assembled 
in Nostoc sp. ATCC 53789 and GSV 224.14,15 Cryptophycin 1 (Figure 1.4) is 
the major representative of the family containing dozens of naturally occurring 
analogues and is constructed from four subunits: phenyl-octenoic acid (unit 
A), 3-chloro-O-methyl-D-tyrosine (unit B), methyl β-alanine (unit C), and L-
leucic acid (unit D).16 The crp gene cluster elucidated in the Sherman 
laboratory is an unusual mosaic polyketide synthase (PKS)/non-ribosomal 
peptide synthetase (NRPS) assembly (Figure 1.5) that has shown flexibility in 
using unnatural starter units to produce novel cryptophycins. Another 
interesting variation in the cryptophycin biosynthetic pathway is the formation 
of a 16-membered macrocyclic ring instead of the more common 14-
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Figure 1.3: Cryptophycins 1 and 52 with units A, B, C, and D highlighted. 
 Two key transformations in the biological assembly of the 
cryptophycins are the closure of the macrocyclic peptolide ring and the 
installation of the C2!-C3! β-epoxide. The full-length chain intermediate is 
cyclized and released from the biosynthetic machinery by the terminal serine 
hydrolase-like cryptophycin thioesterase (CrpTE).17 As part of the post- 
PKS/NRPS tailoring, the epoxide is installed regio- and stereospecifically by 
the cytochrome P450 cryptophycin epoxidase (CrpE).18 Both enzymes were  




























































Cryptophycin 1  
Figure 1.4: The crp gene cluster and the deduced PKS/NRPS assembly line. Domains within the 
crp assembly line are shown as circles (PKS) and squares (NRPS) with abbreviations (AT, 
acyltransferase; KS, ketosynthase; CM, C-methyltransferase; DH, dehydratase; KR, ketoreductase; 
ACP, acyl carrier protein; A, adenylation; C, condensation; PCP, peptidyl carrier protein; OM, O-
methyltransferase; E, epimerase; TE, thioesterase). 
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successfully reconstituted by heterologous expression in E. coli and 
displayed remarkable in vitro activity and flexibility. The substrate tolerance of 
these enzymes will be critical to employing them as biocatalysts in the 
development of an efficient chemoenzymatic synthesis of novel cryptophycin 
compounds for the treatment of cancer.   
The cryptophycins have been shown to be some of the most potent 
tubulin stabilizing agents discovered to date.16,19 Initial evaluation of the 
cryptophycins identified this class of depsipeptides as excellent antifungal 
agents, especially against Cryptococcus fungal species. Further testing 
revealed that cryptophycins were exceptionally potent antiproliferative agents, 
active against a range of human solid tumor cell lines.20,21 As reported by 
Smith et al.,20 treatment with cryptophycin 52 caused marked and marginally 
reversible depletion of microtubules. Closer analysis of the activity of 
cryptophycins revealed binding to tubulin to inhibit microtubule polymerization, 
leading to hyperphosphorylation of Bcl-2 and triggering of the apoptotic 
cascade.22-24 Cryptophycin 1 was demonstrated to depolymerize existing 
microtubules25 into unique ring structures composed of only a few tubulin 
heterodimers26,27 and markedly restrict microtubule dynamics at much lower 
concentrations than either paclitaxel or vinblastine.22,28 Despite potent 
suppression of microtubule function, however, cryptophycin did not 
significantly decrease polymer mass, giving it an advantage over paclitaxel by 
avoiding increased tubulin expression to release the mitotic block. 
Furthermore, cryptophycin 1 was reported to complex tubulin at microtubule 
ends without copolymerizing with the tubulin or succumbing to cellular efflux 
pumps, suggesting a significant therapeutic advantage over vinca alkaloids in 
duration of intracellular retention.22  
Even more exciting was the observation that cryptophycin 52 - a 
synthetic analogue of cryptophycin 1 identified as the most promising clinical 
candidate - was not a substrate for P-glycoprotein, an active efflux pump 
present in many multidrug resistant (MDR) cancer cell lines.20,29 In 
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comparison studies with other widely-studied antimitotics, such as vinblastine, 
colchicine, and paclitaxel, cryptophycin was found to have 100- to 1,000-fold 
more potent growth suppression in resistant cell lines (Table 1.1).20 However, 
dose-limiting peripheral neuropathy prevented cryptophycin 52 from 
advancing further than Phase II in clinical trials.30-33 In a subsequent study in 
patients with platinum-resistant ovarian cancer, the considerable rate of 
disease stabilization suggested further investigation was warranted.34 The 
potential for cryptophycins to become powerful and effective anti-cancer 
therapeutics therefore urges an in-depth study of the effects of structural 
modifications on pharmacology.35 As a result, extensive medicinal chemistry 
efforts have been undertaken in the search for new analogues with improved 
therapeutic profiles.21,36,37 Similar problems with solubility and toxicity were 
found and overcome for other antimitotic agents, fostering optimism about 
further development of these promising natural product anti-cancer agents.38-
41 
Table 1.1: Antiproliferative effects of well-known antimitotics in cultured human tumor cells 
and their MDR counterparts. 
    IC50 (nM)     
Cell line Vinblastine Colchicine Taxol Cryptophycin 1 
SKOV3 0.65 ± 0.25 9.0 ± 3.0 1.0 ± 0.4 0.007 ± 0.002 
SKVLB1 4200 ± 1700 8000 ± 2400 8000 ± 2000 0.60 ± 0.19 
     resistance factor 6400 890 8000 85 
     MCF-7 3.0 ± 0.8 8.8 ± 3.0 2.5 ± 0.2 0.016 ± 0.002 
MCF-7/ADR 183 ± 14 930 ± 280 4300 ±270 0.017 ± 0.004 
     resistance factor 61 106 1720 1.1 
 
Unit A (Figure 1.4), a polyketide with a pendant phenyl ring and β-
epoxide, is the most amenable subunit for synthetic derivatization, as a 
plethora of substituted phenyl rings maintained excellent potency.21 The best 
remaining chemical space for cryptophycin unit A analogue exploration is 
therefore the incorporation of heterocycles in place of the endogenous 
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pendant phenyl ring. Heterocycle incorporation will expand current structure 
activity relationship (SAR) understanding and the increased number of 
heteroatoms will serve to decrease the hydrophobicity of the parent 
compounds. More hydrophilic cryptophycins (lower partition coefficients, logP) 
should have several benefits, including improved aqueous solubility for 
formulation purposes and decreased hydrophobicity to reduce metabolism 
and nonspecific protein binding,42 hopefully mitigating the toxicity issues 
associated with this class of anticancer agents.  
Heterocycle substitution of the cryptophycins allows a unique 
opportunity to explore the impact of electron demand from the ring on the 
vicinal epoxide. Evidence to date has suggested that cryptophycins bind 
tubulin tightly, but reversibly. However, the presence of a labile epoxide begs 
the question of potentially covalent, reversible protein interactions being 
responsible for the observed tubulin conformational changes and 
exceptionally high potency. Initial experiments measuring cryptophycin 
concentrations after denaturation of co-incubated tubulin found no change in 
drug levels, suggesting reversible, noncovalent binding.22 Additionally, 
pretreatment of cryptophycin with dithiothreitol (DTT), a mimic of nucleophilic 
tubulin sulfhydryl groups, had no effect on cryptophycin activity in the same 
study. Evidence supporting the potential covalent reactivity of the epoxide 
was supplied in several studies on cryptophycin metabolism. Pre-clinical and 
solution stability studies revealed inherent reactivity of the epoxide with water 
leading to a diol, while clinical trials identified the glutathione conjugate as the 
major metabolite.43 Solution studies with model nucleophiles like glutathione 
or methyl thioglycolate may therefore help deconvolute the role of epoxide 
ring opening in tubulin binding and cryptophycin mechanism of action.  
My dissertation research under the mentorship of Professors Scott D. 
Larsen and David H. Sherman was designed to fuse our basic understanding 
of cryptophycin biosynthetic machinery with efficient and flexible synthetic 
methodology to achieve rapid derivatization of unit A and expand anticancer 
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SAR through the construction of a library of novel heterocyclic cryptophycins. 
The specific aims of my research included (1) the development of an efficient, 
flexible, divergent synthetic scheme to rapidly derivatize unit A with a suite of 
heterocycles, (2) attachment of these unit A analogues to endogenous units B, 
C, and D to construct a library of new seco-cryptophycins, (3) enhancing our 
current understanding of chemoenzymatic synthesis through optimization of 
CrpTE and CrpE as biocatalysts for ring closure and epoxidation, and (4) 
exemplification of a unique chemoenzymatic route to selected cryptophycin 
analogues and their implications for cancer treatment. Detailed discussion of 
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Development of an Efficient, Divergent Synthesis of Heterocyclic Unit A 
Analogues 
 
2.1 METHODS FOR THE SYNTHESIS OF CRYPTOPHYCIN UNIT A 
 Of the four subunits that comprise the cryptophycins, unit A is the only 
subunit where significant structural modification has been previously 
performed with demonstrated tolerance.1-3 As noted by Corbett and 
coworkers,4 substituted phenyl ring analogues of unit A have displayed 
antitumor activity with promising pharmacological profiles. By going a step 
further and incorporating heterocycles on unit A, understanding of 
cryptophycin Structure Activity Relationship (SAR) will expand and the 
correlation between epoxide electron-deficiency and binding affinity can be 
determined. First, a strong correlation would be evidence for binding affinity 
to be due, at least in part, to reversible addition of a nucleophile to the 
epoxide. If cryptophycin covalently interacts with tubulin, modulation of the 
electronics of the epoxide should significantly affect the kinetics of addition. 
Second, the presence of heterocyclic unit A-bearing cryptophycins should 
enhance the overall pharmacology of this class of drugs, including improved 
aqueous solubility for formulation purposes and decreased hydrophobicity to 
reduce metabolism and nonspecific protein binding. Therefore, we were 
motivated to establish a selective, scalable, and efficient method for the 
production of unit A analogues varied in the phenyl region to support 
development of improved cryptophycins for the treatment of cancer. 
 Many methods exist for the construction of natural and novel unit A 
fragments, each with its own unique advantages and disadvantages.5,6 The 
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challenge lies in choosing among these methods one which allows a rapid, 
selective, high-yielding synthesis but is also flexible and divergent. That is, 
the synthetic scheme must allow for attachment of a variety of substitutions 
without intensive method development for each, and it must facilitate 
structural diversification at or near the end to avoid multiple parallel 
syntheses. One of the earlier syntheses of unit A developed by Moore and 
coworkers installed the two stereocenters in unit A through the ring opening 
of an oxirane (Scheme 2.1).7 The key steps in this route for installing the 
stereocenters were a Sharpless asymmetric epoxidation and regioselective 
nucleophilic ring opening with trimethylaluminum to give 1,2-diol 4. While this 
method was high yielding and stereoselective, the ring functionality was 
installed at the very beginning using dihydrocinnamaldehyde and was not 
suitable for divergent synthesis. Another oxirane opening synthesis of unit A 
was developed by Furuyama and Shimizu, and relied on a Sharpless 




































Scheme 2.1: Unit A synthesis by Moore and coworkers: regio- and stereoselective ring opening 
of an oxirane.7 Reagents and conditions: (a) (MeO)2P(O)CH2CO2Me, THF, TMG, -78 °C to rt (86%); 
(b) DIBAL-H, THF, -78 °C to rt (90%); (c) L-(+)-DET, Ti(Oi-Pr)4, t-BuOOH, CH2Cl2, -20 °C (94%, >95% 
ee); (d) Me3Al, hexane-CH2Cl2, 0 °C to rt (95%); (e) (MeO)2CMe2, PPTS, CH2Cl2, rt (97%); (f) NBS, 
(MeO)2CMe2, CCl4, hv, rt; (g) DBU, 70 °C, (80%, f-g); (h) 1% aq. HCl-MeOH, rt (93%); (i) 
Bu2Sn(OMe)2, PhMe, Dean-Stark, TsCl, Et3N, 0 °C to rt (82%); (j) TBSOTf, Et3N, CH2Cl2, rt (98%); (k) 
KCN, DMSO, 60 °C (92%); (l) DIBAL-H, CH2Cl2, -78 °C to rt (95%); (m) (MeO)2P(O)CH2CO2Me, TMG, 
THF, -78 °C to rt (83%); (n) LiOH, acetone, 25 °C (95%). 
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oxirane was then opened via palladium-catalyzed hydrogenation with 
isomerization of the intermediate palladium complex. This method was 
shorter and highly stereoselective, but the ring functionality was installed 
through Wittig chemistry likely to be poorly suited for a large number of 
analogues. 
Aldol additions with chiral auxiliaries also found early success in the 
synthesis of cryptophycin unit A, as in the route of Maier and coworkers9 
(Scheme 2.2) that utilized chiral auxiliary 11 with known aldehyde 12. This 
route employed the auxiliary to direct the aldol addition and set the two 
required stereocenters, while a late-stage oxidation and Wittig reaction was 
attractive for derivatization. A subsequent modification by the same group 









































Scheme 2.2: Unit A synthesis by Maier and coworkers: aldol addition with a chiral auxiliary.9 
Reaction conditions: (a) Bu2BOTf, DIPEA, CH2Cl2, -78 °C to rt, 2.5 h (82%); (b) NaBH4, THF-H2O (5:1), 
0 °C to rt, 2 h (76%); (c) TBSCl, Et3N, DMAP, CH2Cl2, 0 °C to rt, 12 h (95%); (d) Ph3P, i-
PrO2CN=NCO2i-Pr, 4-O2NC6H4CO2H, THF, 0 °C to rt, 12 h (70%); (e) NaOH, MeOH, rt, 2 h (94%); (f) 
TBSCl, imidazole, DMF, rt, 12 h (87%); (g) DDQ, CH2Cl2/H2O (20:1), 0 °C to rt, 2.5 h (85%); (h) 
(COCl)2, DMSO, CH2Cl2, -78 °C, 1 h, then Et3N, -78 °C to 0 °C, 2 h; (i) (EtO)2P(O)CH2CO2Et, NaH, 
THF, 0 °C to rt, then addition to the aldehyde, 0 °C, 1 h (95%, h-i); (j) AcOH-H2O-THF (1:1:2), rt, 50 h 
(75%); (k) (COCl)2, DMSO, CH2Cl2, -78 °C, 1 h, then Et3N, -78 °C to 0 °C, 3 h; (l) (EtO)2P(O)CH2Ph, 
n-BuLi, THF, -78 °C, 1 h, then addition of the aldehyde, -78 °C to rt, 7 h (56%, k-l).  
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routes required costly epimerization of the carbon center bearing the hydroxyl 
group in 14, and the olefination necessitated the use of a structurally limited 
pool of aryl aldehyde or aryl phosphonate coupling partners.  
Chemoenzymatic approaches have also been utilized for the synthesis 
of unit A. For example, Sih and coworkers published the first synthesis of unit 
A using enzyme-catalyzed kinetic resolution of a racemate (Scheme 2.3).10 
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Scheme 2.3: Chemoenzymatic approaches to unit A. (Top) Sih and coworkers. Reaction conditions: 
(a) Me2SO4, LDA, THF, -60 °C to 5 °C (92%); (b) 2-propanol-treated Candida rugosa lipase, 0.2 M 
phosphate buffer, rt (48%, ee >96%); (c) DIBAL-H, Et2O, -70 °C (95%); (d) tert-butyl 4-
bromocrotonate, Zn-Pb (18%). (Bottom) Varie et al. Reaction conditions: (a) Trigonopsis variabilis, pH 
7 buffer, glucose (50-62%, >98% de); (b) TBSCl, DBU, DMF (87%); (c) O3, MeOH-CH2Cl2; (d) Ac2O, 
DMAP; (e) NaOH, MeOH (73%, c-e); (f) NaOCl, TEMPO, CH2Cl2 (87%); (g) CF3CO2H, CH2Cl2, TFA, -
15 °C, 2 h (83%); (h) DIBAL-H, PhMe, -78 °C; (i) (MeO)2P(O)CH2CO2Me, TMG, THF (66%, h-i); (j) 
NaOCl, TEMPO; (k) PhMgBr, -78 °C (67%, j-k); (l) Ms2O, Et3N, DMAP, CH2Cl2 (53%).  
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rugosa lipase-catalyzed saponification to furnish the S-acid leaving the R-
isomer 23 untouched. Unfortunately for this route, any phenyl ring 
functionality would need to be present in the starting methyl ester and be 
accepted as a substrate by the enzyme, while the subsequent Reformatsky 
rearrangement to add the terminal carboxyl using a zinc-lead couple was low 
yielding and offered virtually no diastereoselectivity. Varie and coworkers 
published another chemoenzymatic approach starting from (R)-(-)-carvone, 
which was exclusively converted to isomer 27 by Trigonopsis variabilis 
(Scheme 2.3).11 Notably, both stereocenters were installed in a single 
enzyme-catalyzed step, followed by a Baeyer-Villiger oxidation and 1,2-
addition of phenylmagnesium bromide to access the desired unit A fragment. 
While short and potentially divergent, the major drawbacks to this route were 
the poor structural diversity offered by the use of arylmagnesium bromides 





















Scheme 2.4: Unit A synthesis of Martinelli and coworkers: asymmetric crotylboration. Reaction 
conditions: (a) NaH, TBSCl, THF, 0 °C (95%); (b) TEMPO, NaOCl, NaHCO3, CH2Cl2, pH 9.0-9.2 
(91%); (c) 1. di[(-)-α-pinenyl]crotylborane, Et2O, -78 °C, 2. H2O2, NaOAc (67%, 99% ee, 99% de); (d) 
TBAF; (e) TEMPO, NaOCl, NaHCO3; (f) HWE reaction; (g) saponification (85%, d-g).  
 Some of the more recent approaches to unit A and its analogues 
employed Brown crotylboration to significantly improve the introduction of the 
two stereocenters, as in the synthesis of unit A precursor 40 by Martinelli and 
coworkers.12 This method (Scheme 2.4) relied on (E)-crotyl 
diisopinocampheylborane to carry out an enantio- and diastereoselective 
crotylation of aldehyde 37. Subsequent oxidation with hydrogen peroxide 
provided the homoallylic alcohol 38 in over 99% enantiomeric excess and 
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67% overall yield. After cleavage of the TBS protecting group and oxidation, a 
Horner-Wadsworth-Emmons (HWE) reaction and saponification provided 
unsaturated acid 40 primed for introduction into the cryptophycin macrocycle 
or derivatization via the terminal olefin.   
 
2.2 FIRST GENERATION UNIT A SYNTHESIS 
Among the available literature methods, we initially envisioned a 
synthetic route modelled closely on that of Eggen et al.,13 which was 
attractive for utilizing Heck coupling for the late-stage installation of the 
phenyl ring in unit A. This coupling was ideal for derivatization of the unit A 
phenyl ring using diverse aryl iodides. The synthetic scheme was therefore 
adopted for the production of desired unit A analogues through a process that 
forms a terminal olefin as a common precursor to both natural unit A and 
analogues (Scheme 2.5). Briefly, 1,3-propanediol is utilized as the feedstock 
and monoprotected as the para-methoxybenzyl (PMB) alcohol, followed by 
2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO)-mediated oxidation to aldehyde 
42. Brown crotylboration is employed to install the two stereocenters in good 
yield and selectivity. Once isolated, homoallylic alcohol 43 undergoes 
protecting group exchange to mask the secondary alcohol as the tert-
butyldimethylsilyl (TBS) ether and expose the primary alcohol. A perruthenate 
oxidation affords the second aldehyde 45, which is homologated to the critical 
α,β-unsaturated tert-butyl ester olefin 46. This terminal olefin was envisioned 
to provide an excellent handle for rapid diversification to a library of 
heterocyclic unit A analogues. Heck coupling is then employed to append the 
pendant phenyl and the resulting unit A fragments are globally deprotected. 
Considering the divergent and flexible nature of this chemistry, efforts were 
focused on optimizing this scheme for large-scale production of the desired 
compounds (for Experimental Details, see Chapter 6). 
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Scheme 2.5: First generation synthetic route to unit A and analogues developed from Eggen et 
al.13 Reaction Conditions: (a) NaH, DMF, 0 °C, 1 h, then PMBCl, 0 °C to rt (81%); (b) TEMPO, NaOCl, 
NaHCO3, KBr, CH2Cl2, pH 8.5-8.7 (88%); (c) trans-2-butene, KOtBu, nBuLi, (+)-(ipc)2BOMe, BF3-OEt2, 
THF, -78 °C, 3 h; (d) ethanolamine, Et2O, rt; (e) TBSOTf, 2,6-lutidine, CH2Cl2, -45 °C (32%, c-e, 90% 
ee, >95% de); (f) DDQ, H2O, CH2Cl2; (g) TPAP, NMO, 4 Å sieves, CH2Cl2 (48%, f-g); (h) 
(EtO)2P(O)CH2CO2tBu, DBU, LiCl, CH2Cl2 (74%); (i) PhI, Pd(OAc)2, PPh3, Et3N, CH3CN, 80 °C (63%); 
(j) TFA, CH2Cl2, 18 h, then NaHCO3, MeOH, CH2Cl2 (23%).  
Initially, the mono-protection of 1,3-propanediol was challenging given 
poor solvent participation and significant bis-protection. Changing from THF 
to DMF as the reaction solvent and using an excess of the diol afforded 
excellent yield of the singly PMB-protected propanol (41) on up to 25-gram 
scale.14 The subsequent TEMPO oxidation to aldehyde 42 proceeded 
smoothly on small scale, but degraded upon scale-up. A method utilizing 
mechanical stirring to more effectively mix the two-phase reaction and 
adjusting of the sodium hypochlorite oxidant solution to pH 8.5 with solid 
sodium bicarbonate was found to be necessary for good yields on large 
scale.15 Incorporation of the crotyl fragment was accomplished by the Brown 
aldehyde crotylation method16 to afford 43 in excellent diastereoselectivity. 
Yields from crotylation using the Brown method remained low, however, 
despite significant optimization efforts to remove traces of moisture and 
strictly control stoichiometric equivalents. Subsequent silyl ether protection of 
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the secondary alcohol suffered from decomposition of the substrate, but 
proceeded to the product, as did DDQ removal of the PMB protecting group. 
The exposed primary alcohol was then converted to aldehyde 45 using 
tetrapropylammonium perruthenate (TPAP) oxidation conditions. This 
oxidation was variable on larger scale, but was sufficient for the task at hand. 
The tert-butyl ester moiety on 46 was then installed using a Horner-
Wadsworth-Emmons (HWE) coupling with the corresponding phosphonate, 
which was followed by Heck coupling to introduce the terminal phenyl. 
Removal of the silyl ether and tert-butyl ester then liberated free unit A (48). 
Using the optimized synthesis described above, approximately 650 mg of 
natural unit A was produced with assistance from Russell Betts, PhD of 
Alluvium Biosciences, for use in the synthesis of several members of a 
cryptophycin-52 unit B library (data not shown). 
Development of this route in our laboratory for higher throughput 
proved to be problematic. The Brown crotylboration was the most significant 
hindrance to large-scale synthesis, as it proceeded in poor yield with 
competing decomposition of aldehyde 42. In addition, protecting group 
exchange was inefficient (43 to 45), and the second round of oxidation 
provided a volatile silyl ether aldehyde (45) whose isolation was problematic. 
The complexity and low-throughput (0.12% over 11 steps to 48) of this route 
hindered our ability to access the desired quantities of unit A and its 
analogues. 
 
2.3 SECOND GENERATION UNIT A SYNTHESIS 
Recent advances in crotylation technology pioneered in the Krische 
laboratory17-20 allowed significant improvements to the synthetic scheme 
presented above. In this scheme (Scheme 2.6), the TBS protecting group21 
was preferred to the PMB group due to improved stability and reduced side 
products in the Krische crotylation, which replaced the Brown crotylation to 
improve enantioselectivity and ease of reaction. This optimization improved 
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the overall yield of the reaction, and the discovery that the catalyst could be 
recovered and recycled dramatically improved throughput and lowered cost. 
Subsequent TBAF deprotection without prior purification afforded diol 51, 
which was then selectively oxidized using TEMPO. The resulting aldehyde 
(52) was unstable, volatile, and prone to elimination, so great care was taken 
in developing buffered reaction conditions and decreasing handling during 
delivery of the aldehyde to the HWE conditions. The subsequent olefination 
proceeded smoothly to afford the required methyl ester 53 in 52% yield from 
the starting diol. With the desired terminal olefin 53 in hand, the remaining 
task was to find Heck reaction conditions suitable for appendage of both the 
endogenous phenyl ring and a variety of heterocycles into the unit A structure. 
Literature reports suggested that Jeffery conditions22,23 would be both mild 
and versatile for this purpose. Further investigation found suitable 
conditions24-26 using the Herrmann-Beller palladacycle (54) that successfully 
afforded the natural phenyl version of unit A (48), but never successfully 
created heterocyclic derivatives. 

































Scheme 2.6: Second generation synthetic route to unit A and analogues. Reaction conditions: (a) 
NaH, DMF, 0 °C, 1 h, then TBSCl, 0 °C to rt (81%); (b) 50, [Ir(cod)Cl]2, (R)-3-TUNEPHOS, α-methyl 
allyl acetate, Cs2CO3, THF, 90 °C; (c) TBAF, THF (35%, 6:1 dr, b-c); (d) TEMPO, NaOCl, NaHCO3, 
KBr, CH2Cl2, pH 8.5-8.8; (e) (EtO)2P(O)CH2CO2Me, DBU, LiCl, CH2Cl2 (74%, d-e); (f) 54, PhI, K3PO4, 
TBACl, DMF, 80 °C (42%); (g) LiOH, MeOH, H2O, THF (87%).  
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Facing these initial obstacles, a new route to unit A analogues was 
sought that was both short and enabled diversification as a terminal, 
divergent step. As already stated, recent advances in crotylation technology 
created the opportunity for a catalytic process with the potential for recovery 
and recycling of the expensive iridium-based reactive complex.27 This 
crotylation was also highly efficient, as it eliminated the need for a separate 
aldehyde generation and isolation step. Significant product (58) 
decomposition challenges were overcome by preforming the iridium catalyst 
(57, Scheme 2.7), as well as running the reaction at a lower temperature with 
K3PO4 as base instead of Cs2CO3. Furthermore, an Eli Lilly process 
chemistry report12 suggested that tedious protection and deprotection steps 
through the final alcohol oxidation would not be necessary, and that an in situ 
olefination could further shorten the synthetic route. Thus, analogue synthesis 
through olefin cross metathesis (CM), Heck coupling, and Suzuki-Miyaura 






















Scheme 2.7: Synthesis of the Krische auxiliary (50) and iridium crotylation complex (57). 
Reaction conditions: (a) H5IO6, CrO3, CH3CN (52%); (b) 50, (R)-(+)-SEGPHOS, 3-buten-2-yl acetate, 
Cs2CO3, THF, 80 °C (quant.).  
Our final synthesis of intermediate 53, which would serve as the 
common intermediate for unit A and analogues, is summarized in Scheme 
2.8.28 Starting from 1,3-propanediol, monosilylated alcohol 49 was prepared 
as previously reported in excellent yield.21 Treatment of 49 with the Ir 
complex 57, prepared and isolated as described,16 in the presence of α-
methyl allyl acetate afforded the expected crotyl alcohol in a 6:1 dr that was 
sufficiently pure to carry forward without purification. Mosher ester 
analysis29,30 of the diastereomeric mixture of 58 confirmed the correct 
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stereochemistry (3S,4R) and revealed a 95:5 er.‡ Precipitation with pentane 
and filtration allowed recovery of the catalyst, while the filtrate containing 58 
was concentrated and treated with TBAF to liberate crotyl diol 51 in good 
yield from 49. With 51 in hand, a one-pot oxidation/olefination sequence was 
employed to effect chemoselective conversion of the primary alcohol to 
unsaturated ester 53 (>20:1 E/Z).31 The terminal alkene on 53 was then 

















Scheme 2.8: Final efficient, divergent synthesis of key olefin intermediate 53. Reaction 
conditions: (a) NaH, THF, 0 °C, 1 h, then TBSCl, 0 °C to rt (92%); (b) 57, 3-buten-2-yl acetate, K3PO4, 
H2O, THF, 60 °C, 48 h; (c) TBAF, THF (52%, b-c, 6:1 dr, 95:5 er); (d) TEMPO, BAIB, CH3CN, 4 h, 
then Ph3PCHCO2Me, 0 °C to rt (72%, >20:1 E/Z).  
A series of phenyl moieties (4-H, 4-trifluoromethyl, 4-methoxy, and 4-
cyano) was chosen to demonstrate the flexibility of the newly developed 
synthetic scheme. This series was chosen for the wide range of electron 
demand presented and for structural replication of non-native cryptophycins 
produced through precursor-directed biosynthesis.32 As previous methods 
utilized Heck coupling for appending the phenyl on unit A, this was the first 
route explored for analogue creation (Table 2.1). Phosphine-free Pd catalysis 
with aryl iodides 59a-d in acetonitrile proved to be the most versatile for 
reactions with the terminal olefin of 53, but also induced reactivity with the 
α,β-unsaturated methyl ester.33-35 Elimination of the secondary alcohol was 
also evident, likely due to extended heating times, but yields were acceptable 
for analogues 60a-d. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
‡ The MTPA ester was synthesized from purified 58 using (S)-(+)-MTPA acid chloride in anhydrous 
pyridine at 60 °C for 24 h. The 19F NMR spectra of esters prepared from 58 and its enantiomer (from 
(S)-(-)-57) were compared to determine the er (Appendix A).  
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Aryl iodide Product Yield (%)b 
59a 60a 31 
59b 60b 28 
59c 60c 38 
59d 60d 30 
 
aReaction conditions: (a) Pd(OAc)2, 1.1 eq. aryl iodide, Et3N, CH3CN, 85 °C, 18 h. bIsolated yields.  
The second route investigated for flexible analogue generation was CM 
(Table 2.2). In this case, olefin 53 underwent metathesis in the presence of 
Hoveyda-Grubbs II catalyst in dichloromethane at reflux temperature with a 
set of para-substituted styrenes (61a-d).36-38 CM was successful in providing 
the desired analogues 60a-d, but competitive insertion of the α,β-unsaturated 
methyl ester prevented higher yields (Table 2.2). However, this route could 
potentially be further optimized to utilize the full spectrum of styryl building  











Styryl fragment Product Yield (%)b 
61a 60a 30 
61b 60b 23 
61c 60c 26 
61d 60d 8 
 
aReaction conditions: (a) Hoveyda-Grubbs II (5 mol%), 4.0 eq. styryl fragment, CH2Cl2, reflux, 2 h. 
bIsolated yield.  
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blocks available.  
The final route developed for unit A analogue synthesis employed 
Suzuki-Miyaura cross coupling. For this method, the boronic ester 62 was first 
prepared through CM (Table 2.3).39,40 Aryl iodides 59a-d were then coupled 
with 62 using Pd2(dba)3 in a mixture of water and glyme to afford analogues 
60a-d in good yield with little apparent bias for electronics.41 Reactivity can 
also potentially be achieved with aryl bromides and chlorides, thereby 
expanding the set of coupling partners available for this transformation.  



















Aryl iodide Product Yield (%)b 
59a 60a 42 
59b 60b 55 
59c 60c 53 
59d 60d 63 
 
aReaction conditions: (a) Hoveyda-Grubbs II, vinylboronic acid pinacol ester, CH2Cl2, reflux (55%); (b) 
[Pd2(dba)3] (2 mol%), PCy3 (4.8 mol%), K3PO4, DME/H2O (2:1), 85 °C, 2 h. bIsolated yield.  
The olefin 53 was effectively elaborated via Heck reaction, CM, and 
Suzuki-Miyaura coupling, but in terms of efficiency and flexibility, Suzuki 
coupling was clearly superior to previously reported unit A derivatization 
methods.42,43 For this reason, unit A analogue library construction 
commenced using the boronic ester 62 under standard Suzuki conditions with 
aryl and heteroaryl iodides. The coupling was scaled to accommodate 
reactions on approximately 300 mg scale of the boronic ester to provide at 
least 100 mg of each of the resulting methyl esters, and first exemplified 
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using iodobenzene for endogenous unit A methyl ester 55 (Figure 2.1). The 
first set of analogues produced were the 2-, 3-, and 4-pyridyl fragments (63, 
64, and 65, respectively) to explore the impact of the varying nitrogen 
electronics on the conjugated double bond when first installing the epoxide 
and then when measuring potency. In addition, the pyridine analogues were 
an intriguing trio of substrates for probing the tolerance of the subsequent 
macrocyclization by cryptophycin thioesterase (CrpTE, see Chapter 3). The 
methyl pyrazolyl (66), pyrazinyl (67), thiophenyl (68), 2-amino pyrazinyl (72), 
and imidazolyl (73) analogues further increased the heteroatom density on 
unit A to improve aqueous solubility and challenge the previous substrate 
boundaries of the cryptophycin biosynthetic enzymes. Analogues 69 and 70 
were included in the initial library because they represented two extremes of 
electron-withdrawing and electron-donating character among substituted 
phenyls, and served as direct comparisons of the developed technology with 
analogues previously only produced through precursor-directed 
biosynthesis.32 While not a heterocycle, aminobenzyl analogue 71 was 
synthesized to serve as a handle for the attachment of any number of cross-
linkers,33 fluorescent probes, targeting peptides,44 or antibodies45 to utilize the 
cryptophycins for interrogation of protein binding, biological distribution, or 
intracellular localization. Finally, the boronic ester 62 was also included in the 
analogue library because it would enable the attachment of larger and more 
sophisticated heterocycles, which may not be feasible CrpTE substrates, after 
enzymatic cyclization.    
With effective elaboration of 53 via Heck reaction, CM, and Suzuki-
Miyaura coupling and the successful completion of a 13-member unit A 
analogue library, the remaining transformation is the hydrolysis of the diverse 
methyl esters. This was accomplished on fragments 60a-d and 63, 66, and 
67 with LiOH in a 2:2:1 mixture of methanol/water/THF (Scheme 2.9) to yield 
the acids 74a-d, and which should be successful for the remaining esters. 
! 27!
The presence of the free acid now allows attachment of these novel unit A 



























































Figure 2.1: Completed unit A library containing both substituted phenyl and heterocycle 
analogues. αSynthesized on small-scale and identified by QTOF-MS; later synthesized on large scale 















Scheme 2.9: Hydrolysis of the methyl esters 60a-d to the carboxylic acids 74a-d. Reaction 
conditions: (a) LiOH!H2O, MeOH/H2O/THF (2:2:1), rt.  
In summary, a short and efficient synthesis has been established to 
intermediate 53 (4 steps, 34% overall yield) from which flexible coupling 
methods provide access to a broad range of phenyl or more highly 
functionalized aromatic and heteroaromatic moieties in the synthesis of unit A 
analogues. The paucity of robust synthetic routes and the surprising flexibility 
of the coupling chemistry merited its inclusion in a recent review of 
approaches to cryptophycin modifications.47 Now with this strategy in place, 
! 28!
the remaining objective involves coupling of the analogues to units B, C, and 
D to generate seco-cryptophycin intermediates. Our laboratory has previously 
demonstrated that solid phase synthesis48 followed by cryptophycin 
thioesterase and epoxidase-mediated chemoenzymatic assembly32,49,50 
enable rapid production of cryptophycin anticancer agents. The versatile unit 
A synthetic strategy reported here is therefore expected to open new 
opportunities to produce unique cryptophycin analogues for on-going drug 
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Reconstitution and Optimization of Cryptophycin Thioesterase for 
Chemoenzymatic Macrocyclization 
 
3.1 INTRODUCTION TO CRYPTOPHYCIN THIOESTERASE 
  Many polyketide synthase (PKS), nonribosomal peptide synthetase 
(NRPS), and fatty acid synthase (FAS) biosynthetic secondary metabolite 
pathways contain terminal thioesterases (TEs) to assist in product off-loading 
through either hydrolysis or intramolecular cyclization. These TEs typically 
utilize a Serine/Histidine/Aspartic acid catalytic triad, analogous to many 
serine proteases, to form an acyl intermediate with the Ser through general 
acid/base catalysis of the His and Asp residues.1 The first step in this process 
is recognition and binding of the peptide or polyketide bound to its designated 
peptidyl (or acyl) carrier protein (P[A]CP) via a thioester with the 
phosphopantetheine arm (Figure 3.1). Once bound, a tetrahedral intermediate 
is formed between the peptide thioester and the active site serine, 
appropriately activated by histidine. The tetrahedral intermediate collapses to 
yield an acylenzyme complex that can undergo formation of a second 
tetrahedral intermediate with either water (hydrolysis) or an intramolecular 
hydroxyl (macrolactonization). Collapse of this second intermediate then 
liberates either the free acid or the macrocyclic natural product and 
regenerates the active site.  
Bacteria are a rich source of natural products, and they utilize TEs 
within their biosynthetic machinery for one of two major transformations.2 The 
first transformation is basic hydrolysis of chain elongation intermediates to 
liberate free acid products, such as in the case of the polyketide metabolite 
! 33!
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Figure 3.1: Diagram of the basic mechanism of a thioesterase. A) Recognition and binding of PCP 
(blue)-bound substrate in the peptide binding site (yellow). B) Formation of first tetrahedral 
intermediate with the serine and stabilization in the oxyanion hole (red). C) Collapse to expel the PCP 
and formation of second tetrahedral intermediate with intramolecular hydroxyl. D) Collapse of second 
tetrahedral intermediate. E) Return of active site to resting state and release of the macrolactone.  
tautomycetin produced by Streptomyces sp. CK4412.3 The characterized 
tautomycetic gene cluster tmc contains a dimeric α,β-hydrolase-type 
thioesterase similar in structure to other Type I PKS TEs. The action of the 
TE at the end of module 9 releases the fully extended polyketide as a 
carboxylic acid (Figure 3.2), and post-PKS maturation is presumed to then 
catalyze decarboxylative dehydration. A subtype of TE hydrolysis is then the 
release of a free acid that spontaneously undergoes decarboxylation to form 
a natural product with an unusual terminal alkene. An example of this 
uncommon tailoring is the tandem sulfotransferase (ST) and TE domains in 



















































































hydroxy-acyl-ACP intermediate, TE hydrolysis, decarboxylation, and sulfate 
elimination follow to afford the mature product.  
!
Figure 3.2: Thioesterase functions in three distinct biosynthetic pathways. A) Terminal 
hydrolysis of the chain elongation product of the tautomycetin pathway to yield a free acid. B) Off-
loading of the sulfonated intermediate by the TE in CurM results in decarboxylation and sulfate 
elimination to produce the terminal alkene curacin A. C) Differential action of pikromycin TE results in 
the production of the 12- and 14-membered macrolactones 10-deoxymethynolide and narbonolide, 
respectively.   
The second major type of reaction catalyzed by bacterial biosynthetic 
TEs is cyclization. One example of macrocyclization is the well-characterized 










































































prematurely to terminate polyketide synthesis with PikAIII, yielding the 12-
membered macrolactone 10-deoxymethynolide (Figure 3.2). Alternatively, 
continued elongation by PikAIV and then TE intervention results in the 14-
membered macrolactone narbonolide. Employing a pentaketide phosphonate 
mimic allowed crystallization of this TE with the substrate mimic bound and 
revealed important structural considerations affecting ring-closure in the 
pikromycin pathway. A hydrophobic pocket exists close to the active site 
serine in the immediate vicinity that presumably functions as the substrate 
recognition and binding site. This chamber opens to a narrower channel that 
serves as a hydrophobic environment for the bound substrate. The co-crystal 
structure further suggests the presence of a hydrophilic barrier at the exit of 
the channel inducing substrates to curl back upon themselves for ring closure. 
This narrow hydrophobic binding pocket with an exit that induces a 
conformation change in the substrate enabling macrocyclization appears to 
be a common strategy employed by many biosynthetic TEs, including the 
DEBS pathway6 and likely the cryptophycin pathway as well. While the 
nonspecific hydrophobic contacts within these active sites afford poor 
!
Figure 3.3: TE processing of the cryptophycin PKS/NRPS-derived chain elongation 
intermediate provides either the free acid through hydrolysis or the macrolactone through 




































substrate specificity, they support the use of biosynthetic TEs as versatile 
biocatalysts for macrocyclization reactions.   
The cryptophycin TE (CrpTE) mediates the termination and cyclization 
of the mixed PKS/NRPS-derived chain elongation intermediate to give the 16-
membered macrolactone between C2 and C16, while hydrolysis to the acid is 
a competing side reaction (Figure 3.3). To explore the substrate tolerance 
first hinted at by the diverse array of products produced both naturally7-10 and 
from feeding studies,11 CrpTE was cloned and expressed in E. coli and used 
with chemically synthesized seco-cryptophycin N-acetylcysteamine (SNAc) 
thioester substrates.12 Enzymatic activity for CrpTE was successfully 
reconstituted in vitro after heterologous expression and purification using Ni 
agarose resin, and the results from enzymatic reactions with the synthetic 
substrates revealed a 40-fold decrease in cyclization when the pendant 
phenyl ring was absent on unit A, underscoring the essential function of this 
ring for macrocyclization. In addition, the presence of a chlorine on the ring of 
unit B was not necessary for efficient cyclization, and CrpTE was insensitive 
to the presence or absence of methyl substituents on unit C. Compared to 
other macrolactone-forming TEs in the epothilone and surfactin biosynthetic 
pathways, CrpTE was 60 times more efficient at cyclization under comparable 
conditions.12 Seufert, Beck, and Sherman13 then demonstrated the first 
application of CrpTE to the macrocyclization of solid-supported 
acylsulfonamide substrates for the production of cryptophycins. The 
extraordinary tolerance and efficiency displayed by CrpTE has thus 
encouraged our continued efforts to develop it as a highly efficient and 
flexible biocatalyst for chemoenzymatic production of substantial quantities of 
novel cryptophycins.  
 
3.2 SYNTHESIS OF NOVEL SECO-CRYPTOPHYCIN SNAC-THIOESTER SUBSTRATES 
 In the natural biosynthetic system, a peptidyl carrier protein (PCP)-
bound substrate is shuttled between domains. This PCP anchors the chain 
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elongation intermediate through a phosphopantetheine arm, which must be 
mimicked to access CrpTE activity. Previous research revealed that SNAc 
was structurally identical to the terminus of the phosphopantetheine arm and 
an excellent stand-in for PKS and NRPS substrates.12,14-16 Therefore, SNAc 
was employed here to generate synthetic seco-cryptophycin thioester 
substrates for enzymatic macrolactonization by CrpTE.  
The substrates were synthesized in the reverse order of biosynthesis 
starting with unit D using a route previously reported in the Sherman lab12 
with minor modifications (Scheme 3.1). The original synthesis reporting direct 
thioesterification of (S)-leucic acid (75) using SNAc in acetone with EDC and 
NaHCO3 was not successful, so an alternative transformation was sought. To 
decrease the number of protection and deprotection steps, a direct protection 
of the alcohol using pyridine with boc anhydride was developed to access 76. 
Although the yield of 76 was low, the inexpensive, commercially available 
starting material allowed the reaction to be run on scale, and solvent 
exchange from DMF to THF simplified purification and improved the yield.  
!
Scheme 3.1: Synthesis of seco-cryptophycin SNAc-thioester substrates for CrpTE-mediated 
macrocyclization. Reaction conditions: (a) (Boc)2O, pyridine, THF, rt (27%); (b) SNAc, EDC, HOBt, 
DIPEA, CH2Cl2, rt (46%); (c) 4 N HCl/dioxane, rt, then (R)-3-(Boc-amino)-2-methylpropionic acid, EDC, 
HOBt, DIPEA, THF, rt (32%); (d) 4 N HCl/dioxane, rt, then 87, EDC, HOBt, DIPEA, THF, rt (70%); (e) 























































82, R = N
N
83, R = N
N(Boc)2N
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The thioester 77 was constructed using SNAc and the common coupling 
reagents EDC and HOBt. Initial attempts at this coupling using catalytic 
dimethylaminopyridine (DMAP) resulted in significant recovery of the free acid 
through aminolysis of the newly formed thioester. This decomposition 
pathway was confirmed when the same problem was observed using 
piperidine to deblock Fmoc-protected starting material. As a result, all 
nucleophilic amines were excluded from contact with the peptide thioester 77 
and all subsequent thioester-containing intermediates.!
!
Scheme 3.2: Synthesis of unit B from D-tyrosine methyl ester. Reaction conditions: (a) SO2Cl2, 
AcOH, Et2O, rt; (b) (Boc)2O, NaHCO3, THF/MeOH (4:1), rt (89%, a-b); (c) MeI, K2CO3, acetone, reflux 
(79%); (d) LiOH!H2O, THF/H2O (4:1), rt (quant.).  
Unit C was the next subunit for incorporation and was purchased from 
Sigma as (R)-3-(Boc-amino)-2-methylpropionic acid. Deprotection of 76 with 4 
N HCl in dioxane and standard coupling conditions with EDC and HOBt then 
afforded dipeptide thioester 78 in moderate yield. Recent studies have 
identified MSNT and NMI as better coupling reagents for the formation of the 
hindered ester, with yields of 78 as high as 61% (J. Schmidt). Then, unit B 
was first prepared synthetically from D-tyrosine methyl ester using the 
unpublished method of W. Seufert, with minor modification (Scheme 3.2). 
Chlorination with sulfuryl chloride followed by boc protection of the 
hydrochloride salt afforded chlorotyrosine 85. Subsequent methylation and 






















coupling. This coupling was achieved by treating 78 with 4 N HCl/dioxane and 
reacting the resulting amine with 87 and EDC/HOBt. With 79 in hand, the final 
step to seco-cryptophycins was attachment of either unit A or any of the 
prepared analogues using identical coupling conditions. As of the time of 
writing this dissertation, four complete seco-cryptophycins had been 
completed: natural phenyl (80), 2-pyridyl (81), methylpyrazolyl (82), and 2-
(boc-amino)pyrimidinyl (83).  
Analogous chemistry exists for the synthesis of these seco-
cryptophycins supported on solid phase,13 but attempts to copy this 
procedure were unfruitful, possibly due to the lack of availability of the 
originally used safety-catch PEGA resin. In addition, the maximum swelling 
diameter of the resin was determined to be very near the lower size limit of 
CrpTE, which suggested poor diffusion of the enzyme into the support matrix.  
 
3.3 PRODUCTION OF CrpTE AND OPTIMIZATION OF ENZYMATIC ACTIVITY 
 The expression and purification of CrpTE was carried out as previously 
reported by Beck et al. as the pET28b construct in E. coli strain BL21 
(DE3).12 Briefly, 1 L cultures of 2XYT media containing 50 μg/mL kanamycin 
were inoculated with an LB starter culture and grown to OD600 of 0.6-0.8 at 37  
!
Figure 3.4: SDS-PAGE gel depicting purification of CrpTE. Lane 1, Invitrogen Benchmark™ 
protein ladder; lane 2, whole cell protein after induction; lane 3, insoluble lysate pellet; lane 4, lysate 
soluble fraction; lane 5, resin flow through; lane 6, purified CrpTE; lane 7, Invitrogen Benchmark™ 
protein ladder.  







°C. Overexpression was induced by the addition of 100 μM IPTG at 30 °C for 
approximately 16 h. CrpTE was purified on Ni agarose resin to >95% purity 
and matched the expected average mass of 35,550 Da (Figure 3.4). A yield of 
approximately 6 mg protein/liter culture was obtained as calculated from a 
Coomassie standard curve using bovine serum albumin (BSA). Purified 
protein aliquots were stored in phosphate buffer, snap frozen in liquid 
nitrogen, and stored at -80 °C until needed. 
 
3.3.1 Confirmation of In Vitro Activity and Promiscuity 
 Successful implementation of CrpTE as a biocatalyst in the production 
of cryptophycin analogues requires substantial inherent substrate promiscuity. 
Small-scale enzymatic reactions were therefore carried out on CrpTE with 
both natural and heterocycle-bearing cryptophycin substrates. The ability of 
CrpTE to load and cyclize cryptophycins was first tested with natural 
substrate after expression of E. coli BL21 (DE3) containing the pET28b crpTE 
plasmid. Reactions were set up in 1.7 mL Eppendorf tubes and contained 100 
μM protein, 500 μM substrate (in DMSO), 5% (v/v) DMSO, and 100 mM 
sodium phosphate buffer, pH 7.0 in 100 μL total volume. After incubation at 
28 °C for 24 h, reactions were quenched by the addition of double the volume 
of ethyl acetate (2 x 200 μL) and the organics were removed under a stream 
of nitrogen. The residues from these reactions were then used directly for the 
preparation of acetonitrile solutions for LC-QTOF-MS analysis. Gratifyingly, 
the purified CrpTE was found to convert 88 to cryptophycin 4 at levels 
comparable to previous reports12 (Cr4, 63% conversion, Figure 3.5) and had 
little interbatch variability. In a separate study, addition of a second 100 μM 
aliquot of enzyme after 24 h followed by incubation at 28 °C for another 16 h 
increased conversion to the macrolactone from 40% to 60%. Moreover, crude 
cell lysate containing CrpTE was tested for activity and found to be 
approximately equal to purified enzyme, but it was not possible to quantify the 
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Figure 3.5: Recapitulation of CrpTE activity on natural substrate 88. Reaction contained 100 uM 
CrpTE and 500 uM 88 in 50 mM sodium phosphate buffer, pH 7.0 with 10% DMSO at 23 °C for 24 h. 
Reaction analyzed by LC-QTOF-MS using a Phenomenex HydroRP column. Top panel, TIC of LC-
QTOF-MS; middle panel, EIC searching for [M+H]+ of 88 and Cr4; bottom panel, UV absorbance at 
280 nm. Conversions were calculated as the ratios of the macrocycle UV trace AUCs to remaining 
starting material and free acid UV trace AUCs. 
amount of CrpTE in the lysate and was thus not the preferred preparation for 
enzymatic reactions. Nevertheless, the use of crude cell lysate would be a 
viable option for preparative scale reactions. 
The activity of CrpTE was then expanded to unnatural cryptophycin 
substrates containing 2-, 3-, and 4-pyridyl rings, as well as a pinacol boronic 
ester, on unit A. Under the standard reaction conditions described above, 
CrpTE displayed remarkable flexibility in the cyclization of all of the tested 
heterocyclic unit A analogues (Table 3.1 and Figure 3.6) with impressive 
conversion. Surprisingly, the 3-pyridyl unit A substrate was cyclized with a 
higher efficiency than the natural substrate, suggesting a positive effect for 
the pyridine nitrogen in cyclization when located in the 3- position on the ring 
of unit A. It is possible this effect was achieved through the ring nitrogen 
inducing a favorable binding mode for cyclization or by associating with active 
site water to disfavor hydrolysis. Conversions were calculated from the ratios 




Figure 3.6: LC-QTOF-MS spectra (EIC) of CrpTE enzymatic reactions. Top panel shows reaction 
using natural substrate as a control with unreacted substrate (89), desired macrocycle (90), and 
hydrolysis side product (91) indicated. Subsequent panels show product distribution with a suite of 
unnatural heterocyclic substrates. Reaction: 100 µM CrpTE, 50 mM sodium phosphate, pH 6.5, 500 
µM substrate, 10% DMSO, 23 oC, 18 h. 
Table 3.1: Comparison of cyclization, hydrolysis, and no reaction of natural and heterocyclic 
cryptophycin substrates of CrpTE. Conversions were calculated as the ratios of the macrocycle UV 
trace AUCs to remaining starting material and free acid UV trace AUCs. 
Substrate Cyclization (90) Hydrolysis (91) Unreacted (89) 
Control 63% 27% 10% 
89a 37% 60% 3% 
89b 73% 19% 7% 
89c 61% 39% 0% 
89d 18% 82% 0% 
 
3.3.2 CrpTE Timecourse Study 
 Traditionally, the CrpTE reactions were allowed to proceed overnight or 
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majority of enzymes are significantly shorter. Therefore, delineating the 
lifetime of CrpTE in our in vitro reaction conditions could reduce the need for 
labor-intensive steps and maximize enzymatic conversion through the 
addition of aliquots of enzyme in regular intervals according to the lifetime of 
CrpTE. A simple timecourse study was thus conducted on CrpTE with 
substrate 88 under standard reaction conditions (Figure 3.7). As can be seen 
from the table, CrpTE continued to be active up to 8 h, after which negligible 
increases in product conversion was observed. An effective lifetime of 8 h 
!
Figure 3.7: CrpTE timecourse study to determine enzyme lifetime. Reaction conditions: 100 µM 
CrpTE, 50 mM sodium phosphate, pH 7.0, 500 µM 88, 5% DMSO, 28 oC. Conversions were calculated 
as the ratios of the macrocycle UV trace AUCs to remaining starting material and free acid UV trace 
AUCs. 
was therefore determined for CrpTE, which represented a potential 
advancement towards developing an effective enzyme dosing regimen for 
future chemoenzymatic synthesis. 
 
3.3.3 CrpTE Tolerance of Reaction Buffer pH and Temperature 
The pH of the buffer in an enzymatic reaction has been demonstrated 
to significantly impact protein and/or substrate stability, as well as enzymatic 
activity, as can reaction temperature. We also speculated that pH might affect 
the relative rates of hydrolysis versus cyclization. Therefore, a series of 



























23 °C and 28 °C. pH values outside of this range would likely result in protein 
denaturation and were not tested. Interestingly, CrpTE activity was insensitive 
to pH values ranging from 6.0 to 8.0, as conversions for the 2-pyridyl 
substrate 89a were all within 5% (Figure 3.8) of each other. However, as high 
as 11% hydrolysis of the SNAc thioester in the no enzyme control was 
observed when the buffer pH was 8.0 (data not shown). Furthermore, little 
variation was found when comparing conversions at the two temperatures 
tested. Considering these results, CrpTE reactions were all performed in 
buffer at the optimal pH values of 6.5 or 7.0 at ambient room temperature. 
!
Figure 3.8: CrpTE tolerance of reaction temperature and pH. Reaction conditions: 100 µM CrpTE; 
50 mM sodium phosphate, pH 6.0, 6.5, or 8.0; 500 µM 89a; 10% DMSO; 23 or 28 oC. Conversions 
were calculated as the ratios of the macrocycle UV trace AUCs to remaining starting material and free 
acid UV trace AUCs. 
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3.4 LARGE-SCALE MACROLACTONIZATION WITH CrpTE 
 To bring large-scale chemoenzymatic production of novel 
cryptophycins one step closer to reality, the enzymatic reactions must be 
scaled and optimized to synthetically relevant levels without needing 
prohibitively large volumes or amounts of enzyme. For this purpose, 20 mL 
solid phase extraction (SPE) reservoirs from Sigma were found to be well-
suited for enzymatic reactions between 5 and 10 mL total volume. In addition, 
































complication noted previously (Y. Ding, personal communication) – and a 
fritted bottom with an outlet port allowed precipitation and filtration of the 
denatured protein from the reaction. A typical large-scale CrpTE reaction was 
modeled on the macrocyclizations performed on solid phase13 and contained 
200 μM purified enzyme, seco-cryptophycin SNAc-thioester substrate, DMSO, 
and 100 mM sodium phosphate buffer, pH 7.0 to complete the reaction 
volume. Once all of the components were combined, the SPE reservoirs were 
tightly capped and agitated at 250 rpm at ambient room temperature. After an 
overnight incubation, the reactions were quenched and protein precipitated 
using twice the volume of ethyl acetate, then filtered though a plug of celite.  
 The first scale-up of the CrpTE macrocyclization aimed to maximize the 
quantity of natural substrate 80 exposed to the enzyme and decrease the 
number of discrete, parallel reactions necessary to convert all of the material 
on hand. Unfortunately, a final concentration of 2.5 mM in a 7% DMSO 
reaction found the substrate to be poorly soluble as indicated by a 
considerable amount of white precipitate suspended in solution. Not 
surprisingly, the corresponding conversion to the macrocycle cryptophycin 1 
was very low in this reaction (Reaction A, Table 3.2). The observation that 
macrocyclization by CrpTE was possible at volumes 50 times greater than 
any previously attempted however was encouraging. Halving the 
concentration of the substrate to 1.25 mM and increasing the volume to 10 
mL with 10% DMSO (Reaction B) still resulted in significant precipitation and 
consequently low conversion. Additional CrpTE was also added to these 
reactions after the initial 18 h incubation to improve conversion, but without 
significant results. Lacking a strong UV signal for these reactions in the LC 
traces it was difficult to quantify the low levels of conversion observed. 
Further reduction in substrate 80 concentration to 0.75 and 0.5 mM finally 
exhibited a response to the improved solubility as increased conversion to the 
macrocycle (Reactions C and D). These results strongly alluded to CrpTE 
activity being limited by substrate solubility. Using 0.5 mM as the maximum 
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tolerated substrate concentration, CrpTE was found to have little preference 
for total reaction volume in the SPE reservoirs (compare Reactions D and E).  
Operating under the hypothesis that the introduction of heterocycles 
would improve cryptophycin solubility, the 2-pyridyl substrate 81 was also 
optimized under large-scale chemoenzymatic conditions. Encouragingly, 
conversion to the macrocycle 92 was acceptable at a starting concentration 
higher than tolerated for the natural phenyl-containing substrate (Reaction G). 
Table 3.2: Optimization of large-scale CrpTE macrolactonization. Reaction conditions: 100 µM 
CrpTE, substrate 80 or 81, 100 mM sodium phosphate, pH 7.0, DMSO, 23 °C, 18 h. Conversions were 
calculated as the ratios of the macrocycle UV trace AUCs to remaining starting material and free acid 
UV trace AUCs. 
 
Reaction [Substrate] ~[CrpTE] Reaction Volume [DMSO] Conversion 
A 80, 2.5 mM 100 µM 5 mL 7% <10% 
B 80, 1.25 mM 100 µM 10 mL 10% <10% 
C 80, 0.75 mM 100 µM 10 mL 10% 17% 
D 80, 0.5 mM 100 µM 5 mL 10% 28% 
E 80, 0.5 mM 100 µM 10 mL 10% 24% 
F 80, 0.5 mM 100 µM 5 mL 25% 31% 
G 81, 1.25 mM 100 µM 10 mL 10% 34% 
H 81, 0.75 mM 100 µM 5 mL 10% 33% 
I 81, 0.5 mM 100 µM 10 mL 10% 41% 
J 81, 0.75 mM 100 µM 5 mL 25% 52% 
 
Decreasing the concentration of 81 again improved the conversion to almost 
twice that observed for the natural substrate (compare Reactions E and I), 
which was strong evidence that CrpTE activity was limited by the solubility of 
its substrate in the reaction medium.  
The increasing conversions observed for substrates 80 and 81 when 
used at either concentrations lower than 0.75 mM or DMSO fractions higher 
than 7% prompted a quick test of CrpTE DMSO tolerance. Reactions with 


























80, R = phenyl
81, R = 2-pyridyl
cryptophycin 1, R = phenyl
92, R = 2-pyridyl
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for conversion to the macrocycle. Conversions were found to increase linearly 
with DMSO concentrations up to 30% and confirmed substrate solubility as 
the limiting factor in chemoenzymatic cyclization by CrpTE (Figure 3.9). 
Applying this newly discovered organic tolerance, large-scale reactions were 
repeated with 80 and 81 using 25% DMSO in the reactions. As can be seen 
for Reactions F and J in Table 3.2, conversion to the macrocyclic product was 
!
Figure 3.9: Initial analysis of CrpTE DMSO tolerance. Reaction conditions: ~100 µM CrpTE, 500 
µM substrate 80, 50 mM sodium phosphate, pH 6.5, 23 °C, 18 h. Conversions were calculated as the 
ratios of the macrocycle UV trace AUCs to remaining starting material and free acid UV trace AUCs.  
significantly increased using the higher DMSO concentration, and visual 
inspection revealed far less precipitate suspended in the reactions. It is 
anticipated that using increased organic fractions with poorly soluble 
substrates will prove to be an excellent optimization strategy in the future.  
 
3.5 OPTIMIZATION OF CrpTE SUBSTRATE SOLUBILITY WITH ORGANIC COSOLVENTS 
 The limited aqueous solubility of the seco-cryptophycin SNAc-
thioesters became apparent during optimization efforts in large-scale 
chemoenzymatic synthesis. The significant hindrance their hydrophobicity 
presented to scale-up was tackled by investigating new methods for 
solubilizing our synthetic substrates with CrpTE in aqueous buffer using 































the application of organic solvents help to improve substrate solubility and 
therefore accessibility, but certain solvent systems could actually increase 
enzyme function and stability.17  
Research into the use of enzymes in organic solvents has been on-
going for decades,18 and one of the more striking examples was the 
observation of lipase activity in organic solvent containing as little as 0.02% 
water.19 In this case, it was necessary to “pH imprint” the proteins by 
lyophilizing them from a buffer at the optimum pH for activity and then 
reconstituting in the mixed organic/aqueous system. The authors further 
described a completely unexpected result where the lipases were only able to 
carry out certain functions to an appreciable extent when in organic solvent, a 
phenomenon termed “medium engineering”.20 However only a limited number 
of enzymes were active directly in organic solvent, namely lipases, but this 
family was expanded to include proteases when lyophilization of subtilisin 
with a competitive inhibitor resulted in an enzyme that was 100 times more 
active in organic solvent than unbound protein.21 Incredibly, this ligand-
induced “enzyme memory” extended to protein stability, affinity, and 
specificity as well. To expand the toolbox of enzymes for use in environments 
other than aqueous buffer, ionic liquids22 and protein engineering23 have also 
been investigated to improve solubility and stability.  
With previous research as inspiration, using CrpTE in mixtures of water 
and common organic solvents was investigated for the production of 
cryptophycin 1. Dimethyl sulfoxide (DMSO), acetone, 1,2-dimethyoxyethane 
(DME), and diglyme were chosen because they were highly miscible in water, 
were capable of completely dissolving the seco-cryptophycin substrates, and 
lacked any potentially nucleophilic functionality that could intercept the acyl-
enzyme intermediate (as previously observed with glycerol). A series of 
reactions were performed in which standard CrpTE conditions were followed 
with substrate 80 except for the addition of 10%, 20%, 30%, 40%, or 50% (v/v) 
organic solvent. The effects of the addition of the common solubilizing agents 
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methylcellulose (MC) and methyl β-cyclodextrin (MCD) to standard 10% 
DMSO reactions were also explored. After overnight incubation at ambient 
room temperature, the reactions were quenched and extracted with twice the 
volume of ethyl acetate (2 x 200 µL). The organic layers were combined and 
dried under a stream of nitrogen, and the residues were dissolved in 100 µL 




Figure 3.10: CrpTE cosolvent study for conversion of substrate 80 to cryptophycin 1. Reaction 
conditions: ~100 µM CrpTE, 500 µM substrate 80, 50 mM sodium phosphate, selected organic solvent, 
pH 6.5, 23 °C, 18 h. Conversions were calculated as the ratios of the macrocycle UV trace AUCs to 
remaining starting material and free acid UV trace AUCs. 
Comparing the results of the CrpTE cosolvent study in Figure 3.10 
revealed exceptional tolerance of CrpTE to a variety of organic solvents up to 



























































Figure 3.11: Comparison of CrpTE conversion efficiency with common solubilizing agents. 
Reaction conditions: 100 µM CrpTE, 500 µM substrate 80, 50 mM sodium phosphate, pH 6.5, 10% 
DMSO, 23 °C, 18 h. Conversions were calculated as the ratios of the macrocycle UV trace AUCs to 
remaining starting material and free acid UV trace AUCs. 
conversion, while diglyme gave nearly twice this conversion. As the organic 
portion was increased to 20% and then 30% of the reaction volume, 
conversion in acetone and DME quickly fell off. This drop was the result of 
significant protein precipitation observed at these concentrations. DMSO and 
diglyme, however, continued to show very high levels of substrate conversion. 
Pushing to even higher organic concentrations of 40% and 50%, DMSO 
maintained enzyme activity with conversions plateauing around 30%, while 
diglyme eventually succumbed to enzyme precipitation and loss of activity. 
The solubilizing agent MC, when used as a 0.4% solution in the reaction 
medium, appeared to have a slight negative affect on substrate conversion 
(Figure 3.11). By comparison, conversion in the presence of 3% MCD was 
more variable but could potentially improve enzymatic activity. Future work on 
the use of cosolvent systems with CrpTE will determine if the high organic 
content simply increases enzyme activity through enhanced substrate 
solubility or improves enzyme efficiency for cyclization through a modified 
enzyme/solvent network. A comparison of the ratios between cyclization and 
hydrolysis under standard and cosolvent conditions should clarify the role of 





























CrpTE is still relatively simple, it represents a significant improvement in 
conversion and the first such use of a biosynthetic macrocycle-forming TE in 
high organic solvent content. It is also an important first step in the 
optimization of the chemoenzymatic synthesis of novel cryptophycins.  
 
3.5.1 Large-Scale Macrocyclizations with Organic Cosolvent 
 The lessons learned from the cosolvent study were applied to the 
optimization of large-scale macrocyclizations with CrpTE. A set of four 5 mL 
reactions were carried out where substrates 80 and 81, at 500 and 750 μM, 
respectively, were incubated with CrpTE under either standard conditions of 
10% DMSO in buffer or 20% diglyme with 1% MCD in buffer for enhanced 
solubility. After agitating in SPE tubes at room temperature overnight, the  
 
!
Figure 3.12: Comparison of large-scale CrpTE conversion under standard conditions and with 
high organic cosolvent. Reactions contained ~100 µM CrpTE, substrate 80 (500 µM) or 81 (750 µM), 
100 mM sodium phosphate, pH 7.0, 23 °C, 160 rpm, 18 h. Conversions were calculated as the ratios 


























80, R = phenyl
81, R = 2-pyridyl
cryptophycin 1, R = phenyl





























reactions were quenched and extracted with 2 portions of 10 mL EtOAc. 
Small aliquots (200 μL) of the organic layers were then removed for LC-
QTOF-MS analysis. Comparing the data in Figure 3.12, the reactions 
conducted with 20% diglyme and 1% MCD had significantly improved 
conversion to the macrocycle. The natural phenyl-bearing unit A substrate (80) 
in particular was responsive to the high organic conditions, with conversion 
increasing from 24.9% to 67.6% under otherwise identical conditions. In 
practice, purification of the product after CrpTE action on substrate 81 
afforded a 35% yield of the new analogue cryptophycin 500 (92). These 
results indicate a major limiting factor in chemoenzymatic synthesis is 
substrate solubility and speak to the strongly positive effect organic 
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Reconstitution and Optimization of Cryptophycin P450 Epoxidase for 
Chemoenzymatic Epoxidation 
 
4.1 INTRODUCTION TO CRYPTOPHYCIN EPOXIDASE 
  Cytochrome P450 monooxygenases (P450s) are a superfamily of 
heme-containing enzymes widely found in the biosynthesis of complex natural 
products in animals, archaea, fungi, bacteria, and plants. The reactions 
catalyzed by P450s depend on the consumption of NAD(P)H and O2 to 
achieve many different types of modifications, including hydroxylation, 
demethylation, aldehyde and ketone formation, and epoxidation.1 Bacterial 
secondary metabolite pathways containing epoxidases are particularly rich 
!
Figure 4.1: Structural diversity observed in natural products containing epoxides installed by 
P450s.  
sources of structural diversity, and several such natural products have been 
isolated (Figure 4.1).2-4 For example, the P450 epoxidase EpoK converts 
epothilones C and D into epothilones A and B, respectively, which are 
substantially more potent biological agents than their des-epoxy 




















































containing natural products and implies a critical biological interaction for this 
functionality.  
 More than half of the 25 cryptophycins produced by Nostoc sp. ATCC 
53789 include a β-epoxide on subunit A of the macrolactone7 installed during 
post-chain elongation tailoring by cryptophycin P450 epoxidase (CrpE). To 
better understand how the epoxide is installed, the crpE gene was previously 
identified in the cryptophycin biosynthetic gene cluster and cloned into a pSJ8 
plasmid to create maltose binding protein (MBP)-tagged CrpE.8 Soluble 
protein with the expected color of a P450 was obtained when expressed as 
this MBP fusion with the assistance of GroEL chaperone. The native redox 
partners for CrpE are not currently known, but activity was realized with 
spinach ferredoxin (Fdx) and ferredoxin NADP+ reductase (Fdr) in conjunction 
with the NADPH regeneration system of glucose-6-phosphate and glucose-6-
phosphate dehydrogenase. A full biochemical and kinetic characterization of 
CrpE was thus performed by Ding et al.8 on the tagged protein in the 
presence of chaperone using spinach Fdx/Fdr and revealed exceptional 
substrate tolerance across units B and C of the cryptophycins. Like many 
human P450s,9,10 CrpE also displayed cooperativity in substrate binding, with 
activity and stability of CrpE improving in the presence of high concentrations 
of testosterone (Y. Ding, personal communication). Considering that β-epoxy 
cryptophycins are 100 times more potent than the des-epoxy analogues,11,12 
CrpE is a critical target for optimization to make it an effective biocatalyst for 
the epoxidation of novel cryptophycin analogues. 
 
4.2 PRODUCTION OF CrpE AND CONFIRMATION OF ENZYMATIC ACTIVITY 
Initial expression of maltose binding protein-fused CrpE (referred to as 
CrpE) using E. coli BL21 (DE3) containing a pSJ8 crpE plasmid with a pGro7 
chaperone in LB media as previously reported afforded CrpE at a 2 μM 
functional concentration using gravity amylose affinity chromatography.8 To 
use CrpE as a biocatalyst for the production of cryptophycins, however, 
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significantly higher concentrations of enzyme were needed. Optimization 
efforts found that TB media supplemented with 2 mM 5-ALA, 0.5 mM 
Fe(NH4)2(SO4)2, and 1 mM thiamine significantly improved yield after growing 
to an OD600 of 0.6 and inducing with 1.5 g/L arabinose and 100 μM IPTG at 
18 °C. The resulting cell pellet was lysed by sonication and soluble protein 
was purified on amylose resin to afford CrpE at a significantly improved 
functional concentration of 14 μM (as assessed using CO binding assay, see 
Chapter 6). This concentration of MBP-CrpE was reproducible under identical 
conditions, and would be sufficient for chemoenzymatic epoxidation.  
 
4.2.1 Confirmation of In Vitro Activity and Promiscuity  
As with CrpTE, successful implementation of CrpE as a biocatalyst in 
the production of unnatural cryptophycin analogues requires substantial 
substrate flexibility. Initial experiments included small-scale enzymatic 
reactions conducted on CrpE with natural and heterocycle-bearing 
cryptophycin substrates. Activity confirmation for CrpE was obtained using  
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Figure 4.2: Confirmation of MBP-CrpE activity with natural substrate 95. Reaction contained 0.2 
µM MBP-CrpE, 100 µg/mL spinach ferredoxin, 0.2 U/mL ferredoxin reductase, 1.4 mM NADPH, 10 
mM glucose-6-phosphate, 8 U/mL glucose-6-phosphate dehydrogenase, 50 mM sodium phosphate, 
pH 6.4, and 5 µM 93 and 95 with 5% DMSO. Top panel, TIC of LC-QTOF-MS; middle panel, EIC for 
[M+H]+ of 93, 94, and 95; bottom panel, UV absorbance at 280 nm. 
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natural substrate cryptophycin 4, which was oxidized to a product with a mass 
matching the corresponding epoxide. When the activity of the isolated CrpE 
was tested against crude cryptophycin 29 (95) obtained from a CrpTE 
reaction on substrate 89, an acceptable level of presumed epoxidation to 94 
was observed in addition to the acid side product of CrpTE (Figure 4.2). 




Figure 4.3: MBP-CrpE enzymatic reactions with heterocyclic cryptophycins. Top panel shows 
reaction using natural substrate 90 as a control with unreacted substrate (90) and putative epoxidated 
product (96) indicated. Subsequent panels show product distribution with a suite of unnatural 
heterocyclic substrates. Reaction conditions: 0.2 µM MBP-CrpE, 100 µg/mL Fdx, 0.2 U/mL Fdr, 1.4 
mM NADPH, 10 mM glucose-6-phosphate, 8 U/mL g-6-p dehydrogenase, 50 mM NaH2PO4, pH 6.4, 5 



































macrocyclic cryptophycins directly from CrpTE reactions without labor- and 
time-intensive purification,13 which will facilitate large-scale epoxidation 
reactions.  
The activity of CrpE was then expanded to cryptophycin substrates 
containing 2-, 3-, and 4-pyridyl rings on unit A. As previously mentioned, 
CrpTE displayed remarkable flexibility in the cyclization of these heterocyclic 
unit A analogs. After workup of the CrpTE reactions and solvent removal, the 
residues were then used directly as substrates for CrpE to test substrate 
promiscuity. Remarkably, oxidation was detected for all substrates used 
against CrpE (Figure 4.3). Oxidation levels were found to be variable, but the 
2-pyridyl substrate (90a) displayed a very high level of oxidation. It was 
possible that participation of the 2-pyridyl nitrogen in the oxidation was 
responsible for the observed conversion. Without significant UV absorbance 
in the LC traces, it was difficult to quantify the levels of conversion seen with 
CrpE. The enzymatic conversions for the 3- and 4-pyridyl substrates were low, 
but these reactions with unnatural substrates have not yet been optimized in 
terms of concentration, time, or solvent. The documented promiscuity is 
previously unknown for this particular P450 and promising for the 
development of CrpE into a useful biocatalyst in the epoxidation of 
cryptophycins. MS/MS and NMR studies are in progress to confirm the 
epoxides as the products of these reactions.  
 
4.3 DESIGN AND APPLICATION OF PUTIDAREDOXIN REDOX PARTNERS FOR CrpE 
 The native Nostoc sp. electron donor partners for CrpE are currently 
unknown, so alternative redox systems must be employed for catalytic 
turnover. Neither E. coli NADPH flavodoxin reductase and flavodoxin, nor rat 
NADPH cytochrome P450 reductase, were viable redox partners for CrpE.8 
The single component RhFRED reductase domain from Rhodococcus sp. 
NCIMB 9784, which found success with the pikromycin P450 PikC,14,15 was 
fused with MBP-CrpE, but the resulting construct was poorly expressed (<1 
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μM functional concentration) and offered no appreciable activity increase over 
Fdx and Fdr. The spinach system offered therefore the best partners for CrpE, 
but these components are cost-prohibitive for large-scale epoxidations. To 
achieve optimal CrpE activity at substrate concentrations of 5 μM, 1,400 μg of 
Fdx and 2.8 units of Fdr would be needed for a single addition of enzyme per 
50 mg of cryptophycin analogue. Having demonstrated increased conversions 
when the reactions were spiked with successive doses of P450 according to 
the lifetime of the enzyme, the cost of adding these particular redox partners 
could increase exponentially. Furthermore, when spread out across a dozen 
analogues, it became clear that an alternative redox system for catalytic 
turnover must be found.  
 The camphor oxidase system from Pseudomonas putida contains the 
P450cam monooxygenase, a FAD-containing, NADH-dependent 
oxidoreductase (putidaredoxin reductase or Pdr), and a 2Fe-2S ferredoxin 
(putidaredoxin or Pdx).16-19 These redox partners represent a viable 
alternative to the expensive Fdx and Fdr in CrpE oxidation reactions because, 
as prokaryotic enzymes, they presumably have more efficient electron 
transfer interactions with CrpE, can be expressed in E. coli at a significant 
cost savings, and use inexpensive NADH instead of NADPH. Furthermore, 
Pdx and Pdr have demonstrated the ability to power catalytic turnover in a 
number of biosynthetic P450s in vitro.20,21 For this purpose, the genes camA 
and camB, encoding for Pdr and Pdx, respectively, were obtained from the 
Pochapsky lab at Brandeis University.  
A dual-expression system for Pdx and Pdr was designed for maximum 
protein yield with minimum purification to avoid decomposition of the sensitive 
iron-sulfur cluster in Pdx. The genes camA and camB were inserted into the 
commercial vector pACYCDuet-1 and the plasmid was cloned into E. coli 
BL21 (DE3) pRARE for coexpression of wild-type Pdx and Pdr. 
Overexpression was performed in 1 L cultures of TB media supplemented 
with 0.2 mM Fe(NH4)2(SO4)2 and 2 mM L-cysteine. Cell mass was lysed and 
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the clarified supernatant containing strong bands for proteins of the 
appropriate size (~14 kDa for Pdx and ~42 kDa for Pdr) was used without 
further purification. The Pdx/Pdr-containing lysate displayed functional P450 
reduction with wild-type PikC for the oxidation of YC-17 (K. Chiou, personal 
conversation). Unfortunately, no activity was observed with CrpE for the 
oxidation of cryptophycin 29 when Pdx/Pdr lysate and NADH were used in 
place of Fdx/Fdr and NADPH.  
The lack of efficient and inexpensive redox partners for CrpE remains a 
substantial impediment to the use of this P450 as a biocatalyst for the 
epoxidation of novel cryptophycins. To meet this challenge, the genome of 
the cryptophycin producer Nostoc sp. ATCC 53789 was isolated for 
sequencing to identify the native CrpE electron transfer partners. Once 
identified, the genes can be excised and subsequently expressed in E. coli for 
significantly improved CrpE epoxidation efficiency. In addition, chemical 
methods for epoxidation of the cryptophycins have already found use and 
could be employed as an alternative to enzyme-catalyzed epoxidation.22-27 
The installation of the epoxide still remains the most daunting aspect of 
cryptophycin synthesis, however, and new chemical methods will need to be 
investigated for improved yield and selectivity with heterocyclic cryptophycin 
analogues.28-32  
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Future Directions for the Cryptophycins 
 
 The cryptophycins are some of the most potent microtubule disrupting 
agents discovered to date,1-3 and have proven to be powerful cytostatic 
agents capable of arresting the growth of P-glycoprotein-expressing multidrug 
resistant (MDR) human carcinoma cell lines.4-6 The potential for 
cryptophycins to become powerful anticancer agents and the efficient, 
divergent unit A analogue synthesis now in place7 demands further 
investigation of their structure-activity relationship (SAR), as well as 
interrogation of their mechanism of action through the construction of 
chemical probe analogues. In addition, the initial substrate tolerance2,8,9 
demonstrated by the biosynthetic enzymes CrpTE and CrpE warrants their 
continued development as biocatalysts in a chemoenzymatic synthesis of 
novel cryptophycins on an unprecedented preparative scale. Finally, we have 
a unique opportunity to build upon our understanding of the structural 
features of CrpTE and CrpE that enable flexibility to maximize analogue 
compatibility and engineer superior biocatalysts.  
 
5.1 GENERATION OF A LIBRARY OF NOVEL HETEROCYCLIC UNIT A-CONTAINING 
CRYPTOPHYCINS 
  With the optimization of our synthetic scheme and production of 
heterocyclic unit A analogues, these analogues can be incorporated with 
units B, C, and D via solution phase or solid-supported peptide coupling 
(Figure 5.1). These linear substrates are then incubated with CrpTE to 
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cleave the tetra-subunit peptolide from SNAc or the solid support and 
catalyze the macrocyclization. Finally, CrpE or an optimized synthetic 
transformation will install the epoxide to generate novel cryptophycins for 
biological analysis. With the marriage of our chemoenzymatic technology and 
heterocyclic unit A synthesis, we are now poised to actively pursue a new 
class of cryptophycin analogues as powerful anticancer drugs. 
!
Figure 5.1: Chemoenzymatic synthesis of heterocyclic cryptophycins using CrpTE and CrpE as 
biocatalysts. Linear depsipeptide substrates can be produced through either solid (A) or solution 
phase synthesis (B). Heterologously expressed CrpTE intercepts thioester or sulfonamide to effect 
macrocyclization (C) and CrpE performs oxidation (D) to complete analogue synthesis. 
Improving pharmacokinetic and pharmacodynamic properties via the 
incorporation of heteroatoms is possible through the lowering of CLogP and 
protein binding and increasing water solubility.10,11 These modifications are 
expected to decrease the amount of cryptophycin necessary for an effective 
dose and consequently reduce the associated dose-dependent peripheral 
neuropathy. This dose-limiting complication can be directly predicted for any 
new cryptophycins using an in vitro single cell culture neurite inhibition assay 
(F. Valeriote, manuscript in preparation). In this assay, a correlation can be 
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drawn between neurite outgrowth & clonogenic cell survival and clinical 
cytotoxicity. The overall effectiveness of new cryptophycins as anticancer 
therapy can then be evaluated in combination with efficacy and potency 
studies. 
 
5.2 INTERROGATION OF THE INTERACTIONS BETWEEN CRYPTOPHYCIN AND A 
CELLULAR PROTEOME THROUGH THE CONSTRUCTION OF AFFINITY PROBES 
 The binding site for cryptophycin on tubulin has not yet been fully 
characterized, nor has any significant attempt been made to identify other 
protein binding partners of cryptophycin. We can approach these problems in 
a number of ways by synthesizing valuable affinity probes based on parent 
cryptophycins (Figure 5.2). The first approach is to append biotin tags onto 
cryptophycin (97) to conduct pull-down assays. This method has worked well 
for other anticancer agents,12,13 and involves incubating biotin-labeled 
cryptophycins with a cellular proteome, after which they are treated with 
streptavidin-coated beads to pull down proteins or complexes that bind 
cryptophycins. Denaturing the streptavidin beads releases any proteins 
associated with the probe for characterization and identification. Activity  
!






















































































Figure 5.3: Multidimensional protein identification (MudPIT) approach for the identification of a 
cryptophycin interactome. Path A: an alkyne-based affinity probe is incubated in a biological 
environment and then fused with a reporter tag for visualization of cryptophycin localization. Path B: a 
biotin-coupled cryptophycin probe is incubated with a cellular proteome and immobilized on a solid 
support for sequence identification.  
Based Protein Profiling (ABPP) and MudPIT14-17 are even more powerful 
extensions of this method for the exploration of cellular binding (Figure 5.3). 
This technique requires the construction of cryptophycins possessing alkynes 
(101) (or azides) reactive in Cu(I)-catalyzed click chemistry.18 After incubation 
with a target population of proteins in vivo, a reporter bearing a!
complementary azide (or alkyne) can flag bound proteins for visualization in 
vitro and mass spectrometric identification.19 !
Another approach to characterizing the biological interactions of 
cryptophycin exploits the photolabile properties of certain moieties to 
covalently label proteins. For this purpose, benzophenone reagents have 
previously been synthesized on unit A (100),20 and other reagents, such as 
tetrafluorophenyl azide (98) or trifluoromethylphenyl diazirine (99), can also 
be used in the light-induced labeling of peptides for identification by mass 
spectrometry.21,22 Covalent labeling of proteins will deconvolute the specific 
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side chains and amino acids on tubulin directly involved in cryptophycin 
binding.  
 
5.2.1 Characterization of CrpTE and its Active Site 
 In addition to human protein interactions, cryptophycin probes may 
expand our understanding of the biosynthetic enzyme CrpTE. We pursued the 
crystallization of CrpTE with a linear cryptophycin substrate blocked in its 
ability to undergo cyclization (Figure 5.4) to predict enzyme flexibility around 
unit A. This SNAc-loaded substrate had a selective methylation on the 
hydroxyl that participates in the cyclization. The hypothesis was that the 
hydroxyl would no longer function as a nucleophile and stall the holo-CrpTE 
for crystallization and X-ray crystal structure analysis. In the absence of a 
productive macrocyclization pathway, however, hydrolysis of the acyl-enzyme 
intermediate predominated and only trace substrate bound protein was 
observed by LC-MS (see Chapter 6). Furthermore, crystallization of CrpTE as 
either the wild type and as a variety of mutants has so far eluded our 
collaborators in the Smith lab (S. Bernard) at the University of Michigan, so 
long-lived substrate binding may be a prerequisite for successful protein 
crystallization.  
!
Figure 5.4: Diagram of the methylated cryptophycin depsipeptide for capture of acylated CrpTE. 
In a continuing effort to map the active site of CrpTE, a phosphonate-
based cryptophycin substrate could be prepared to irreversibly bind to the 
active site serine in CrpTE (Scheme 5.5).23-25 Using a seco-cryptophycin 
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already on hand, the SNAc can be cleaved using piperidine and unit A 
protected as the silyl ether P1. Treatment with thionyl chloride should then 
furnish acid chloride P2 ready for conversion to phosphonate P3 under basic 
conditions. Deprotection with camphorsulfonic acid (CSA) liberates the 
covalent CrpTE substrate P4, which can likely be further transformed into the 
fluorophosphonate using diethylaminosulfur trifluoride (DAST) should the 
phosphonate prove ineffective. This relatively simple modification of subunit 
D into the phosphonate using known chemistry26-28 should provide a linear 
substrate capable of being recognized !
!
Scheme 5.5: Proposed synthesis of a phosphonate-based CrpTE acylating agent. Reaction 
conditions: (a) SOCl2; (b) (RO)2P(O)Me, LHMDS; (c) CSA.  
by CrpTE and then irreversibly binding, hopefully allowing for crystallization of 
the resulting holo-TE without significant active site deformation or substrate 
hydrolysis. As the binding site of CrpTE becomes clear, we can begin to 
predict which cryptophycin analogues will be enzymatically processed. 
Meanwhile, site-directed mutagenesis can be employed to enhance the 
inherent flexibility and accommodate more sophisticated and sterically bulky 
unit A analogues. 
 
5.3 CrpE STRUCTURE DETERMINATION 
 Understanding the active site architecture of CrpE may help us to 




































have an excellent protein crystallographer, Dr. Larissa Podust at UCSF, 
collaborating on the study of CrpE. As substrate-protein interactions become 
clearer, protein engineering can again be performed to enhance the inherent 
promiscuity of this P450. Combined with the identification of the native redox 
partners from the full genome sequencing of Nostoc sp. ATCC 53789, these 
advancements will help us optimize CrpE as a biocatalyst in the epoxidation 
of cryptophycins.  
 
5.4 THE CRYPTOPHYCINS AS CONJUGATE THERAPIES 
 If the neurotoxic side effects of the cryptophycins prove to be 
recalcitrant to the incorporation of heterocycles in subunit A, the creation of 
cryptophycin conjugates may hold promise for their continued clinical 
development.29 An example of this strategy is the recent FDA approval of 
Genentech’s trastuzumab emtansine (trade name Kadcyla™), which is a 
novel antibody-drug conjugate of the maytansine30 derivative mertansine and 
the monoclonal antibody trastuzumab.31 Like the cryptophycins, mertansine is 
a cytotoxic microtubule inhibitor that binds tubulin and was found to be too 
toxic for monotherapy. However, when conjugated to the antibody 
trastuzumab, which targets Human Epidermal Growth Factor Receptor 2-
positive (HER2+) cancer, mertansine was released only in these cancer cells. 
As a result, trastuzumab emtansine improved survival by 5.8 months in 
comparison to other chemotherapeutic combinations in women with 
trastuzumab-resistant HER2+ breast cancer.31 Indeed, initial steps towards 
the use of cryptophycins as conjugates have been taken with the attachment 
of fluorescently labeled RGD peptides through unit C.32 Fluorescence 
microscopy subsequently proved integrin-mediated internalization and 
lysosomal localization of the cryptophycin prodrug. Cryptophycin conjugates 
with targeting macromolecules may therefore prove to be a highly successful 
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  Unless otherwise stated, all reactions were performed with no extra 
precautions taken to exclude moisture or air. Anhydrous, inhibitor-free 
tetrahydrofuran (THF), 1,2-dimethoxyethane (DME), diglyme, and DMF were 
purchased from Sigma-Aldrich, and anhydrous acetonitrile (ACN) was 
purchased from Acros and used as received. Dichloromethane (DCM) was 
shaken with sat. aq. NaHCO3, distilled from CaH2, and degassed with three 
rounds of a freeze-pump-thaw procedure. All other chemicals were obtained 
from Sigma-Aldrich, Alfa Aesar, Strem, TCI, NovaBiochem, Advanced 
ChemTec, or ChemImpex and used directly unless otherwise noted.  
1H, 13C, and 19F NMR spectra were recorded on Varian 400 and 500 
MHz NMRs. Proton chemical shifts are reported in ppm referenced to residual 
solvent in CDCl3 (7.26 ppm) or CD3OD (3.31 ppm) as the internal standard; 
carbon chemical shifts are reported in ppm referenced to the centerline of 
residual solvent in CDCl3 (77.16 ppm) or CD3OD (49.0 ppm) as the internal 
standard. Proton spectral data are described as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, b = 
broad), coupling constant (in Hz), and integration. High-resolution mass 
spectra were obtained on an Agilent Accurate-Mass Q-TOF 6520 using a 
Phenomenex Synergi 4u HydroRP (100 x 2.0 mm, 4 μm) column. Analytical 
thin-layer chromatography (TLC) was performed on silica gel 60 F254 TLC 
glass plates with a fluorescent indicator from EMD Chemicals. EMD Silica Gel 
60 Geduran® (particle size 0.040 – 0.063 mm) silica gel was used for flash 
chromatography. Visualization was accomplished by UV fluorescence 
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quenching (254 nm) and by p-anisaldehyde, potassium permanganate, or 
ceric ammonium molybdate staining with heating.  
 
6.1 FIRST GENERATION UNIT A SYNTHESIS 
 
3-((4-methoxybenzyl)oxy)propan-1-ol (41). To a stirred 
solution of 1,3-propanediol (46.25 mL, 0.64 mol) in 175 mL 
anhydrous DMF under argon was slowly added solid NaH (9.62 g, 0.24 mol) 
at 0 oC. The reaction was stirred for 30 min, then treated with slow addition of 
PMBCl (25.0 g, 0.16 mol). The reaction was stirred for an additional 1 h and 
allowed to warm to room temperature overnight, then quenched with sat. aq. 
NH4Cl. Reaction diluted and partitioned between water (100 mL) and ethyl 
acetate (EtOAc, 100 mL). Aqueous layer extracted with EtOAc (150 mL x 3) 
and combined organics washed with brine (250 mL) and dried with Na2SO4. 
Evaporation of the solvent and chromatographic purification (SiO2, 2:1 
hexanes:EtOAc [H:E]) afforded the desired product (41, 25.51 g, 81%) as a 
clear, colorless oil. TLC Rf = 0.15 (3:1 H:E). 1H NMR (CDCl3, 400 MHz) δ 
7.25 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 4.45 (s, 2H), 3.80 (s, 3H), 
3.77 (m, 2H), 3.63 (m, 2H), 2.49 (bs, 1H), 1.85 (m, 2H) ppm.  
 
3-((4-methoxybenzyl)oxy)propanal (42). Sodium 
hypochlorite solution (47 mL, 10-15%, Sigma) was diluted 
1:1 with water to an approximate concentration of 0.35 M and buffered to pH 
8.5 with solid NaHCO3. A separate two-phase system of KBr (303 mg, 2.55 
mmol) in 50 mL water and 41 (5.0 g, 25.5 mmol) and TEMPO (40 mg, 0.25 
mmol) in 100 mL of CH2Cl2 was cooled to 0 oC with overhead mechanical 
stirring. The NaOCl solution was then added quickly with vigorous stirring. 
After 5 min, reaction quenched by the addition of 5 mL sat. aq. KHSO4 with 
10% KI. Organic layer separated and washed with sat. aq. Na2S2O3 and brine, 






purification (SiO2, 2:1 hexanes:EtOAc [H:E]) afforded the desired product (42, 
4.33 g, 88%) as a clear, colorless oil. TLC Rf = 0.45 (1:1 H:E). 1H NMR 
(CDCl3, 400 MHz) δ 9.77 (s, 1H), 7.24 (d, J = 8.8 Hz, 2 H), 6.87 (d, J = 8.8 Hz, 
2H), 4.46 (s, 2H), 3.78 (m, 5H), 2.67 (dt, J = 2.0, 12.0, 2H) ppm.   
 
(3S,4R)-1-((4-methoxybenzyl)oxy)-4-methylhex-5-en-
3-ol (43). A round bottom flask (RBF) was equipped with 
a magnetic stir bar and flame-dried under vacuum. The 
flask was charged with anhydrous, inhibitor-free THF (75 
mL) under argon, then cooled to -78 oC and treated with KOtBu (49.1 mL, 1.0 
M in THF, 48.46 mmol). The trans-2-butene was then condensed in the 
reaction (~11.0 g, 0.196 mol) and a 1.6 M solution of nBuLi in hexanes (30.26 
mL, 48.46 mmol) was added dropwise. Reaction warmed to -45 oC for 10 min 
and then cooled back to -78 oC. The (+)-(ipc)2BOMe (15.48 g, 48.95 mmol) 
was then added to the reaction as a solution in 30 mL anhydrous THF and 
stirred for 30 min at -78 oC. The BF3!OEt2 (6.04 mL, 48.95 mmol) was then 
added followed by slow addition of aldehyde 42 (9.50 g, 48.95 mmol) 
dissolved in 10 mL anhydrous THF. Reaction stirred at -78 oC for 2 h, then 
quenched by the addition of sat. aq. NH4Cl and warmed to room temperature. 
The volatiles were removed under vacuum and the residue partitioned 
between water and EtOAc. The organic layer was washed with water and 
brine and then dried with Na2SO4. The residue after solvent evaporation was 
resuspended in Et2O, treated with ethanolamine (3.25 mL, 53.85 mmol), and 
stirred at room temperature overnight. Finally, the solvent was removed and 
the resulting residue was flash purified (4:1 H:E) to yield a mixture of crotyl 
alcohol 43 and isopinocampheol, which was carried through to the next step 







methylhex-5-en-3-yl)oxy)dimethylsilane (44). To a 
stirred solution of mixed 43 in dry CH2Cl2 (100 mL) at -78 
oC under argon was added 2,6-lutidine (10.74 mL, 92.22 
mmol). The TBSOTf (10.59 mL, 46.11 mmol) was then added dropwise and 
the reaction was stirred for 3.5 h at -78 oC. Reaction quenched by the 
addition of sat. aq. NH4Cl and warmed to room temperature. The reaction 
was diluted with water, and the organic layer was washed with brine and 
dried with Na2SO4. Evaporation of the solvent and chromatographic 
purification (SiO2, hexanes to 10:1 H:E) afforded the desired product (44, 
5.84 g, 32%, 2 steps) as a clear, light yellow oil. TLC Rf = 0.90 (3:1 H:E). 1H 
NMR (CDCl3, 400 MHz) δ 7.24 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 
5.76 (m, 1H), 5.00 (s, 1H), 4.96 (d, J = 3.2 Hz, 1H), 4.40 (q, J = 11.6 Hz, 2H), 
3.81 (s, 3H), 3.75 (m, 1H), 3.47 (m, 2H), 2.29 (m, 1H), 1.67 (m, 2H), 1.00 (d, 
J = 6.8 Hz, 3H), 0.88 (s, 9H), 0.03 (s, 6H) ppm.  
 
(3S,4R)-3-((tert-butyldimethylsilyl)oxy)-4-methylhex-5- 
enal (45). A stirred solution of 44 (2.49 g, 6.83 mmol) in 
CH2Cl2 (50 mL) at room temperature was treated with solid 
DDQ (1.71 g, 7.51 mmol) and water (1.84 mL, 0.10 mmol). 
After 1 h, reaction was quenched by the addition of sat. aq. NaHCO3 and 
diluted with water and CH2Cl2. The organic layer was washed with sat. aq. 
NaHCO3 and brine, then concentrated under vacuum. The crude residue was 
then dissolved in 100 mL CH2Cl2 containing 4 Å molecular sieves (585 mg) 
and NMO (961 mg, 8.20 mmol). The reaction was next treated with TPAP 
(120 mg, 0.342 mmol) and stirred at room temperature for 1 h. The solvent 
was removed under vacuum from an ice bath and the residue was flash 
purified (SiO2, 10:1 H:E) to afford the desired product (45, 800 mg, 48%, 2 








MHz) δ 9.78 (s, 1H), 5.74 (m, 1H), 5.05 (m, 2H), 4.19 (m, 1H), 2.49 (m, 2H), 
2.36 (m, 1H), 1.02 (d, J = 6.4 Hz, 3H), 0.88 (s, 9H), 0.07 (s, 6H) ppm.  
 
 (5S,6R,E)-tert-butyl 5-((tert-butyldimethylsilyl)oxy)-
6-methylocta-2,7-dienoate (46). The 
(EtO)2P(O)CH2CO2tBu (5.89 mL, 25.08 mmol), DBU 
(2.25 mL, 15.05 mmol), and LiCl (744 mg, 17.56 mmol) 
were suspended in 75 mL anhydrous ACN at room temperature and stirred 
vigorously for 30 min. This solution was then added dropwise to a stirred 
solution of 45 (3.04 g, 12.54 mmol) in 50 mL anhydrous ACN under argon at 
room temperature. After 2 h, the reaction was quenched by the addition of sat. 
aq. NH4Cl and concentrated under vacuum. The residue was partitioned 
between water and EtOAc, and the organic layer was washed with sat. aq. 
NH4Cl and brine, then dried with Na2SO4. Evaporation of the solvent and 
chromatographic purification (SiO2, 20:1 H:E) afforded the desired product 
(46, 2.87 g, 74%) as a clear, light yellow oil. TLC Rf = 0.75 (9:1 H:E). 1H NMR 
(CDCl3, 400 MHz) δ 6.80 (m, 1H), 5.75 (m, 2H), 5.02 (m, 2H), 3.66 (m, 1H), 





phenylocta-2,7-dienoate (47). A solution of 46 
(788 mg, 2.64 mmol), iodobenzene (330 μL, 2.90 
mmol), and Et3N (1.95 mL, 13.99 mmol) was prepared in an oven-dried 
pressure vessel with anhydrous, degassed ACN (10 mL). Solid Pd(OAc)2 (30 
mg, 0.132 mmol) and PPh3 (69 mg, 0.26 mmol) were then added and reaction 
purged with argon. Reaction heated at 80 oC for 18 h and then concentrated 
in vacuo. The residue was dissolved in CH2Cl2 and washed with 0.5 M HCl 










of the solvent and chromatographic purification (50 g Biotage, SiO2, 4:1 
H:CH2Cl2 to 3:1 H:CH2Cl2, 35 mL/min) afforded the desired product (47, 618 
mg, 63%) as a clear, yellow oil. TLC Rf = 0.60 (toluene). 1H NMR (CDCl3, 400 
MHz) δ 7.30 (m, 4H), 7.21 (m, 1H), 6.83 (m, 1H), 6.37 (d, J = 16.0 Hz, 1H), 
6.16 (dd, J = 8.0, 16.0 Hz, 1H), 5.74 (dd, J = 4.0, 15.6 Hz, 1H), 5.01 (m, 1H), 
3.74 (m, 1H), 2.29 (m, 3H), 1.43 (s, 9H), 1.09 (d, J = 6.8 Hz, 3H), 0.91 (s, 9H), 
0.06 (s, 6H) ppm. 
 
(2E,5S,6R,7E)-5-hydroxy-6-methyl-8- 
phenylocta-2,7-dienoic acid (48, unit A). A 
solution of 47 (380 mg, 0.91 mmol) in 10 mL 
CH2Cl2 was treated with TFA (350 μL, 4.55 mmol) 
and stirred at room temperature overnight. The solvent was then removed 
under vacuum and the residue was redissolved in 10 mL of 1:1 MeOH/CH2Cl2. 
The resulting solution was treated with solid NaHCO3 (612 mg, 7.28 mmol) 
and stirred at room temperature overnight. The reaction was quenched by the 
addition of 1.0 M HCl and volatiles were removed under vacuum. The 
recovered residue was partitioned between water and CH2Cl2, and the 
organic layer was washed with dilute HCl and brine. Evaporation of the 
solvent and chromatographic purification (10 g Biotage, SiO2, 1% 
MeOH/CH2Cl2 + 0.5% HOAc, 25 mL/min) afforded the desired product (48, 51 
mg, 23%) as a clear, colorless oil. TLC Rf = 0.40 (5% MeOH/CH2Cl2 + 1% 
HOAc). 1H and 13C NMR spectra matched those previously reported.1  
 
6.2 SECOND GENERATION UNIT A SYNTHESIS 
 
3-((tert-butyldimethylsilyl)oxy)propan-1-ol (49). To a 
stirred solution of 1,3-propanediol (5.0 g, 65.71 mmol) in 
150 mL anhydrous DMF under argon was slowly added solid NaH (2.63 g, 








TBSCl (9.90 g, 65.71 mmol), added portionwise. The reaction was stirred for 
an additional 1 hour and allowed to warm to room temperature, then 
quenched with sat. aq. NH4Cl. Reaction partitioned between water (100 mL) 
and ethyl acetate (EtOAc, 100 mL). Aqueous layer extracted with EtOAc (150 
mL x 3) and combined organics washed with brine (250 mL) and dried with 
Na2SO4. Evaporation of the solvent and chromatographic purification (SiO2, 
4:1 H:E) afforded the desired product (49, 9.59 g, 81%) as a clear, colorless 
oil. TLC Rf = 0.70 (3:1 H:E). 1H NMR (CDCl3, 400 MHz) δ 3.83 (m, 4H), 2.64 
(s, 1H), 1.76 (q, J = 5.5 Hz, 2H), 0.89 (s, 9H), 0.05 (s, 6H) ppm; 13C NMR 
(CDCl3, 100 MHz) δ 63.06, 62.51, 34.31, 26.00, 18.29, -5.39 ppm. 
 
4-cyano-3-nitrobenzoic acid (50). Periodic acid (19.56 g, 
85.82 mmol) was dissolved in anhydrous ACN (80 mL) 
under argon at room temperature. After 15 min, solid CrO3 
(981 mg, 9.81 mmol) and 4-methyl-2-nitro-benzonitrile (3.98 
g, 24.52 mmol) were added successively and the reaction 
was stirred at room temperature overnight. Next, the reaction was decanted 
and the supernatant concentrated under vacuum. The residue was then 
partitioned between sat. aq. Na2CO3 and CH2Cl2. The resulting precipitate 
was removed by filtration and the filtrate was adjusted to pH 1 with 6 M HCl. 
The aqueous layer was then extracted with EtOAc and the combined organics 
were extracted with 1.0 M Na2CO3, followed by acidification to pH 1 with 6 M 
HCl. The resulting precipitate was collected by filtration and dried under 
vacuum. Recovered 2.92 g of pure 50 as a fine, yellow solid (62%). 1H NMR 
(d6-DMSO, 400 MHz) δ 8.62 (s, 1H), 8.37 (s, 1H), 8.23 (s, 1H), 3.39 (bs, 1H) 
ppm. 
 
 (3S,4R)-4-methylhex-5-ene-1,3-diol (51). To an oven-










0.33 mmol), (R)-C3-TUNEPHOS (390 mg, 0.66 mmol), 50 (252 mg, 1.31 
mmol), and Cs2CO3 (857 mg, 2.63 mmol) under argon. To this was added 13 
mL of anhydrous, inhibitor-free THF and 3-buten-2-yl acetate (3.33 mL, 26.26 
mmol). Reaction was heated at 90 oC for 30 min and then cooled to room 
temperature. Compound 49 (2.5 g, 13.13 mmol) was then added as a solution 
in a minimum amount of THF and reaction stirred at 90 oC under argon in the 
sealed vessel for 24 h. Next, the reaction was cooled to room temperature 
and diluted with pentane (~100 mL). The resulting precipitate was collected 
by filtration and the filtrate was concentrated under vacuum. The recovered 
residue was then dissolved in 75 mL of anhydrous THF under argon and 
treated with a 1.0 M solution of TBAF in THF (14.44 mL, 14.44 mmol). After 
stirring at room temperature for 1 h, reaction was concentrated under vacuum 
and the residue was purified (SiO2, 1:1 H:E) to afford the desired product as a 
clear, light yellow oil (51, 586 mg, 35%, 2 steps) as a clear, colorless oil. TLC 
Rf = 0.25 (1:1 H:E). 1H NMR (CDCl3, 400 MHz) δ 5.73 (m, 1H), 5.09 (m, 2H), 
3.84 (m, 2H), 3.63 (m, 1H), 2.98 (bs, 1H), 2.68 (bs, 1H), 2.23 (m, 1H), 1.68 
(m, 2H), 1.02 (d, J = 5.0 Hz, 3H) ppm. 
 
 (5S,6R,E)-methyl 5-hydroxy-6-methylocta-2,7-
dienoate (53). A stirred solution of 51 (67 mg, 0.51 
mmol) in ACN (700 μL) and PBS buffer, pH 7.5 (300 μL) 
at 0 oC was treated with solid TEMPO (4 mg, 0.026 
mmol) and BAIB (180 mg, 0.56 mmol). After 3 h, the reaction was warmed to 
room temperature, quenched with sat. aq. Na2S2O3, and diluted with water 
and CH2Cl2. The organic layer was washed with sat. aq. NaHCO3 and dried 
with Na2SO4, then concentrated under vacuum. In a separate flask, a stirred 
suspension of LiCl (13 mg, 0.31 mmol) in 1.5 mL anhydrous ACN at room 
temperature was treated with (EtO)2P(O)CH2CO2Me (52 μL, 0.29 mmol) and 
DBU (46 μL, 0.31 mmol). This reaction was stirred for 10 min and then a 






the reaction was quenched with sat. aq. NH4Cl and diluted with water (10 mL) 
and CH2Cl2 (10 mL). The organic layer was washed with water and brine, 
then dried with Na2SO4. Evaporation of the solvent and chromatographic 
purification (SiO2, 2:1 H:MTBE) afforded the desired product (53, 37 mg, 39%) 
as a clear, colorless oil. TLC Rf = 0.50 (1:1 H:MTBE). 1H NMR (CDCl3, 400 
MHz) δ 7.03 (m, 1H), 5.92 (d, J = 15.6 Hz, 1H), 5.74 (m, 1H), 5.14 (m, 2H), 
3.73 (s, 3H), 3.56 (m, 1H), 2.44 (m, 1H), 2.36-2.22 (m, 2H), 1.84 (s, 1H), 1.06 
(d, J = 6.8 Hz, 3H) ppm. 
 
 (2E,5S,6R,7E)-methyl 5-hydroxy-6-methyl-8-
phenylocta-2,7-dienoate (55). The cataCXium® 
(54, 8 mg, 0.008 mmol), TBACl (45 mg, 0.163 
mmol), and K3PO4 (70 mg, 0.33 mmol) were 
added to a dry, screw top vial and purged with argon. The iodobenzene (22 
μL, 0.20 mmol) and a solution of 53 (30 mg, 0.163 mmol) in 1.0 mL of 
anhydrous DMF were then added and the sealed reaction stirred at 80 oC 
overnight. The reaction was next cooled to room temperature and partitioned 
between dilute NH4Cl and CH2Cl2. The combined organic layers were then 
washed with brine and dried with Na2SO4. Evaporation of the solvent and 
chromatographic purification (SiO2, 4:1 H:E + 0.1% Et3N) afforded the desired 
product (55, 18 mg, 42%) as a clear, colorless oil. TLC Rf = 0.50 (1:1 
H:MTBE). 1H NMR (CDCl3, 400 MHz) δ 7.36-7.25 (m, 4H), 7.20 (m, 1H), 7.04 
(m, 1H), 6.44 (dd, J = 9.2, 15.6 Hz, 1H), 6.11 (m, 1H), 5.90 (m, 1H), 3.71 (s, 
3H), 3.66 (m, 1H), 2.50-2.31 (m, 3H), 1.14 (d, J = 6.8 Hz, 3H) ppm. 
 
(2E,5S,6R,7E)-5-hydroxy-6-methyl-8- 
phenylocta-2,7-dienoic acid (48, unit A). A 
solution of 55 (94 mg, 0.036 mmol) in a 1:1:0.5 
mixture of methanol/water/THF (1.5 mL) was 










overnight. Reaction then quenched with 2.0 M HCl and diluted with water (2 
mL) and EtOAc (2 mL). Aqueous layer extracted with EtOAc (2 mL x 2) and 
combined organics washed with brine and dried with Na2SO4. Solvent 
removed in vacuo and residue purified by flash chromatography (SiO2, 5:95 
MeOH:CH2Cl2 + 0.1% HOAc) to afford 48 as a clear, light yellow oil (77 mg, 
87%). TLC Rf = 0.25 (5:95 MeOH:CH2Cl2 + 1% HOAc). 1H and 13C NMR 
spectra matched those previously reported.1 
 
6.3 FINAL, DIVERGENT SYNTHESIS OF UNIT A AND ANALOGUES 
 
3-((tert-butyldimethylsilyl)oxy)propan-1-ol (49). To a 
stirred solution of 1,3-propanediol (5.0 g, 65.71 mmol) in 
250 mL anhydrous THF under argon was slowly added solid NaH (2.63 g, 
65.71 mmol) at 0 oC. The reaction was stirred for 30 min, then treated with 
slow addition of TBSCl (9.90 g, 65.71 mmol) dissolved in minimal THF. The 
reaction was stirred for an additional 1 hour and allowed to warm to room 
temperature, then quenched with sat. aq. NH4Cl. Solvent removed by rotary 
evaporation and residue partitioned between water (100 mL) and ethyl 
acetate (EtOAc, 100 mL). Aqueous layer extracted with EtOAc (150 mL x 3) 
and combined organics washed with brine (250 mL) and dried with Na2SO4. 
Evaporation of the solvent and chromatographic purification (SiO2, 4:1 
hexanes:EtOAc [H:E]) afforded the desired product (4, 11.56 g, 92%) as a 
clear, colorless oil. TLC Rf = 0.30 (4:1 H:E). 1H NMR (CDCl3, 400 MHz) δ 
3.81 (m, 4H), 2.65 (s, 1H), 1.76 (q, J = 5.5 Hz, 2H), 0.89 (s, 9H), 0.07 (s, 6H) 
ppm; 13C NMR (CDCl3, 100 MHz) δ 63.01, 62.49, 34.34, 26.01, 18.31, -5.36 
ppm; HRMS (ESI+) 191.1462 m/z [M+H]+ (C9H23O2Si requires 191.1467).  
 
Krische crotylation complex (57). To an over-dried sealed flask was added 
[Ir(cod)Cl]2 (500 mg, 0.74 mmol), (R)-(+)-SEGPHOS (910 mg, 1.49 mmol), 50 




solids were suspended in anhydrous THF (7.5 mL) and treated with 3-buten-
2-yl acetate (375 μL, 2.96 mmol). The reaction was stirred at room 
temperature for 30 min and then at 80 oC for 2 h. Once the reaction had 
cooled to room temperature, it was filtered, washing with THF (10 mL). The 
filtrate was then diluted with pentane (100 mL) and the precipitate was 
recovered by filtration and dried under vacuum to yield the crotylation 
complex 57 as a fine, orange powder (1.76 g, quant.).  
 
 (3S,4R)-1-((tert-butyldimethylsilyl)oxy)-4-methylhex-
5-en-3-ol (58). To an oven-dried, 100 mL RBF under 
argon was added 57* (2.45 g, 2.34 mmol), K3PO4 (4.96 g, 
23.37 mmol), anhydrous THF (25 mL), and water (2.10 mL, 116.85 mmol). 
The 3-buten-2-yl acetate (5.93 mL, 46.74 mmol) and 49 (4.45 g, 23.37 mmol) 
were then added and reaction stirred at room temp for 30 min. The reaction 
was then warmed to 70 oC and stirred under argon for 24 h. Next, the reaction 
was cooled to room temp and filtered, washing with THF. The filtrate was 
concentrated in vacuo and diluted into pentane (150 mL). Solids removed (or 
recovered to recycle the catalyst)† by filtration and eluent concentrated by 
rotary evaporation to afford crude 58 as a 6:1 diastereomeric mixture. This 
residue was used without further purification. TLC Rf = 0.45 (10:1 H:MTBE 
x2). 1H NMR (CDCl3, 500 MHz) δ 5.82 (m, 1H), 5.04 (m, 2H), 3.86 (m, 1H), 
3.79 (m, 1H), 3.67 (m, 1H), 3.33 (minor, d, J = 2.5 Hz), 3.17 (major, d, J = 2.5 
Hz, 1H) 2.23 (m, 1H), 1.61 (m, 2H), 1.02 (d, J = 7.0 Hz, 3H), 0.88 (s, 9H), -
0.05 (s, 6H) ppm; 13C NMR (CDCl3, 125 MHz) δ 140.71, 115.10, 75.03, 62.77, 
43.94, 35.52, 25.87, 18.15, 15.74, -5.55 ppm; HRMS (ESI+) 245.1931 m/z 
[M+H]+ (C13H29O2Si requires 245.1937). 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
*!Flash chromatography of the catalyst did not give significantly higher yield or selectivity, so 
purification was omitted.!!






 (3S,4R)-4-methylhex-5-ene-1,3-diol (51). The residue 
from above was dissolved in anhydrous THF (~95 mL) 
under argon, slowly treated with TBAF (1.0 M in THF, 23.0 
mL, 23.37 mmol), and stirred for 1 h at room temperature. Reaction then 
quenched with sat. aq. NH4Cl (50 mL) and THF removed by rotary 
evaporation. Residue partitioned between water (100 mL) and EtOAc (100 
mL). The aqueous layer was washed with EtOAc (100 mL x 3) and combined 
organics dried with Na2SO4 and concentrated. Residue purified by 
chromatography (50 g Biotage® KP-SIL column, 1:1 H:E, 45 mL/min) on a 
CombiFlash Retrieve® system to afford the desired product (51, 1.60 g, 52% 
[2 steps]) as a clear, light orange oil. TLC Rf = 0.20 (1:1 H:E). 1H NMR (CDCl3, 
500 MHz) δ 5.73 (m, 1H), 5.09 (m, 2H), 3.84 (m, 2H), 3.63 (m, 1H), 2.98 (bs, 
1H), 2.68 (bs, 1H), 2.23 (m, 1H), 1.68 (m, 2H), 1.02 (d, J = 5.0 Hz, 3H) ppm; 
13C NMR (CDCl3, 125 MHz) δ 140.28, 116.53, 75.00, 61.73, 44.68, 35.38, 




dienoate (53). A solution of 51 (920 mg, 7.07 mmol) 
and TEMPO (110 mg, 0.707 mmol) in ACN (75 mL) was 
treated with solid [bis(acetoxy)iodo]benzene (BAIB, 2.62 g, 8.13 mmol) and 
stirred at room temperature for 2 h. Reaction cooled to 0 oC and treated with 
solid methyl(triphenylphosphoranylidene) acetate (3.07 g, 9.19 mmol). 
Reaction stirred for an additional hour, allowing it to warm to room 
temperature. Reaction then quenched with sat. aq. Na2S2O3 and solvent 
removed in vacuo. Recovered material partitioned between water (200 mL) 
and DCM (200 mL). The aqueous layer was extracted with DCM (100 mL x 2) 
and combined organics washed with brine and dried with Na2SO4. Solvent 
removed by rotary evaporation and residue flash purified (SiO2, 4:1 H:E) to 









H:E). 1H NMR (CDCl3, 500 MHz) δ 7.01 (m, 1H), 5.91 (d, J = 15 Hz, 1H), 5.73 
(m, 1H), 5.13 (m, 2H), 3.72 (s, 3H), 3.56 (m, 1H), 2.43 (m, 1H), 2.24 (m, 2H), 
1.81 (bs, 1H), 1.05 (d, J = 5.0 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz) δ 
166.92, 145.96, 139.65, 123.32, 117.10, 73.49, 51.61, 44.01, 37.18, 16.32 
ppm; HRMS (ESI+) 207.0995 m/z [M+Na]+ (C10H16NaO3 requires 207.0997).  
 
 (2E,5S,6R,7E)-methyl 5-hydroxy-6-methyl-8-
phenylocta-2,7-dienoate (60a). Heck Reaction: 
Pd(OAc)2 (2 mg, 0.0089 mmol) was added to a 
flame-dried, screw top vial under argon (solid aryl iodides were also added at 
this step) and dissolved in a solution of 53 (34 mg, 0.185 mmol) in anhydrous 
ACN (1.8 mL). The iodobenzene (23 μL, 0.203 mmol) was then added, 
followed by Et3N (258 μL, 1.85 mmol). Reaction stirred at 85 oC for 18 h and 
then cooled to room temperature. Reaction was concentrated in vacuo and 
residue flash purified (SiO2, 2:1 H:MTBE) to afford 13 mg of 60a (31%) as a 
clear, colorless oil. TLC Rf = 0.60 (1:1 H:MTBE). Compounds 60b, 60c, and 
60d prepared through Heck reaction were accessed in an analogous manner. 
Compound 60a: 1H NMR (CDCl3, 500 MHz) δ 7.38 (m, 2H), 7.31 (m, 2H), 
7.24 (m, 1H), 7.05 (m, 1H), 6.48 (d, J = 15.9 Hz, 1H), 6.13 (dd, J = 8.7, 15.9 
Hz, 1H), 5.92 (d, J = 15.8 Hz, 1H), 3.74 (s, 3H), 3.66 (m, 1H), 2.41 (m, 3H), 
1.74 (d, J = 3.9 Hz, 1H), 1.16 (d, J = 6.8 Hz, 3H) ppm; 13C NMR (CDCl3, 125 
MHz) δ 166.89, 145.81, 137.09, 132.27, 130.99, 128.73, 127.62, 126.29, 
123.45, 73.95, 51.64, 43.51, 37.43, 16.96 ppm; HRMS (ESI+) 283.1305 m/z 




octa-2,7-dienoate (60b): 28%; TLC Rf = 
0.60 (1:1 H:MTBE). 1H NMR (CDCl3, 500 MHz) δ 7.56 (d, J = 8.2 Hz, 2H), 










1H), 6.26 (dd, J = 8.6, 16.0 Hz, 1H), 5.93 (d, J = 15.7 Hz, 1H), 3.73 (s, 3H), 
3.70 (m, 1H), 2.45 (m, 3H), 1.71 (d, J = 3.9 Hz, 1H), 1.17 (d, J = 4.6 Hz, 3H) 
ppm; 13C NMR (CDCl3, 125 MHz) δ 166.83, 145.48, 140.62, 133.93, 130.76, 
126.48, 126.44, 125.66 (q, J = 3.8 Hz), 123.67, 73.89, 51.68, 43.45, 37.63, 





2,7-dienoate (60c): 38%; TLC Rf = 0.55 
(1:1 H:MTBE). 1H NMR (CDCl3, 500 MHz) δ 7.30 (d, J = 6.7 Hz, 2H), 7.06 (m, 
1H), 6.86 (d, J = 8.7 Hz, 2H), 5.94 (m, 2H), 3.81 (s, 3H), 3.73 (s, 3H), 2.37 (m, 
3H), 1.77 (d, J = 3.7 Hz, 1H), 1.13 (d, J = 6.8 Hz, 3H) ppm; 13C NMR (CDCl3, 
125 MHz) δ 166.92, 159.27, 145.93, 131.74, 128.69, 127.49, 123.37, 114.13, 
112.94, 73.96, 55.47, 51.64, 43.52, 37.37, 17.03 ppm; HRMS (ESI+) 




30%; TLC Rf = 0.40 (1:1 H:MTBE). 1H NMR 
(CDCl3, 500 MHz) δ 7.59 (d, J = 8.3 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.01 (m, 
1H), 6.46 (d, J = 15.9 Hz, 1H), 6.32 (dd, J = 8.6, 16.0 Hz, 1H), 5.92 (d, J = 
15.7 Hz, 1H), 3.73 (s, 3H), 3.71 (m, 1H), 2.46 (m, 2H), 2.38 (m, 1H), 1.70 (d, 
J = 4.0 Hz, 1H), 1.17 (d, J = 6.9 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz) δ 
166.54, 145.06, 141.40, 135.17, 132.31, 130.15, 126.58, 123.52, 118.86, 
110.48, 73.60, 51.46, 43.19, 37.48, 16.71 ppm; HRMS (ESI+) 308.1266 m/z 
[M+Na]+ (C17H19NNaO3 requires 308.1263). 
 
Cross metathesis. Solid Hoveyda-Grubbs II (9 mg, 0.015 mmol) was added 










The catalyst was dissolved in a solution of 53 (54 mg, 0.293 mmol) in 
anhydrous, degassed DCM (1.17 mL). Styrene (134 μL, 1.17 mmol) was then 
added via syringe and reaction stirred at reflux temperature for 4 h. Reaction 
cooled to room temperature, treated with 50 eq. of DMSO, and stirred at room 
temperature for 12 h. The reaction was then concentrated in vacuo and 
purified by flash chromatography (SiO2, 2:1 H:MTBE) to afford 60a (23 mg, 
30%) as a clear, colorless oil. Spectra were identical to those collected for 
60a above. Compounds 60b, 60c, and 60d prepared through cross 
metathesis were accessed in an analogous manner and had spectra identical 
to those reported above. Compound 60b: clear, light yellow oil (23%). 
Compound 60c: clear, colorless oil (26%). Compound 60d: clear, light yellow 
oil (8%).  
 
Suzuki-Miyaura cross coupling. [Pd2(dba)3] (2 mg, 0.0018 mmol), 
tricyclohexylphosphine (1 mg, 0.0043 mmol), and K3PO4 (32 mg, 0.153 mmol) 
were added to a flame-dried screw top vial under argon and suspended in a 
solution of 62 (28 mg, 0.090 mmol) in anhydrous DME (240 μL). Water that 
had been degassed under vacuum in a sonicator (120 μL) and iodobenzene 
(12 μL, 0.108 mmol) were then added and reaction stirred at 85 oC for 2 h. 
Reaction cooled to room temperature and diluted with water (5 mL) and 
EtOAc (5 mL). The aqueous layer was extracted with EtOAc (5 mL x 3) and 
combined organics washed with brine (10 mL) and dried with Na2SO4. 
Solvent removed in vacuo and residue flash purified (SiO2, 2:1 H:MTBE) to 
afford 60a (10 mg, 42%) as a clear, colorless oil. Spectra were identical to 
those collected for 60a above. Compounds 60b, 60c, and 60d prepared 
through Suzuki-Miyaura coupling were accessed in an analogous manner and 
had spectra identical to those reported above. Compound 60b: clear, light 
yellow oil (55%). Compound 60c: clear, colorless oil (53%). Compound 60d: 






Solid Hoveyda-Grubbs II (190 mg, 0.304 mmol) was added to a flame-dried 2-
neck flask equipped with a reflux condenser under argon and dissolved in 
anhydrous, degassed DCM (20 mL). A solution of 53 (1.12 g, 6.08 mmol) in 
10 mL DCM was then added to the flask. Vinylboronic acid pinacol ester (2.06 
mL, 12.16 mmol) was passed through a plug of activated charcoal 
immediately prior to use and added via syringe to the stirring reaction mixture. 
Reaction heated at reflux temperature for 4 h, then cooled to room 
temperature and treated with 50 eq. of DMSO, stirring overnight, to allow 
removal of colored ruthenium byproducts upon silica purification.2 Reaction 
concentrated and residue purified by flash chromatography (SiO2, 3:1 
pentane:EtOAc) to afford 934 mg of 62 as a clear, light tan oil (50%). 1H NMR 
(CDCl3, 500 MHz) δ 7.01 (m, 1H), 6.52 (dd, J = 7.9, 18.1 Hz, 1H), 5.91 (d, J = 
15.8 Hz, 1H), 5.53 (d, J = 18.1 Hz, 1H), 3.73 (s, 3H), 3.62 (m, 1H), 2.37 (m, 
3H), 1.66 (d, J = 4.2 Hz, 1H), 1.27 (s, 12H), 1.06 (d, J = 6.9 Hz, 3H) ppm; 13C 
NMR (CDCl3, 125 MHz) δ 166.89, 154.28, 145.89, 123.53, 83.44, 73.45, 
51.63, 45.74, 37.13, 24.97, 24.93, 15.78 ppm; HRMS (ESI+) 333.1858 m/z 
[M+Na]+ (C16H27BNaO5 requires 333.1849).  
 
(2E,5S,6R,7E)-5-hydroxy-6-methyl-8- 
phenylocta-2,7-dienoic acid (unit A, 74a). A 
solution of 60a (10 mg, 0.038 mmol) in a 1:1:0.5 
mixture of methanol/water/THF (385 μL) was treated with solid LiOH H2O (5 
mg, 0.115 mmol) and stirred at room temperature for 2 h. Reaction then 
quenched with 0.1 M HCl and diluted with water (2 mL) and EtOAc (2 mL). 
Aqueous layer extracted with EtOAc (2 mL x 2) and combined organics 
washed with brine and dried with Na2SO4. Solvent removed in vacuo and 












HOAc) to afford 74a as a clear, light yellow oil (8.5 mg, 89%). TLC Rf = 0.50 
(5:95 MeOH:DCM + 0.1% HOAc). Compounds 74b, 74c, and 74d were 
hydrolyzed using an identical procedure. Compound 74a: 1H and 13C NMR 
spectra matched those previously reported1; HRMS (ESI+) 269.1149 m/z 




dienoic acid (74b). 90%; TLC Rf = 0.50 
(5:95 MeOH:DCM + 0.1% HOAc). 1H NMR (CDCl3, 500 MHz) δ 7.55 (d, J = 
8.2 Hz, 2H), 7.45 (d, J = 8.2 Hz, 2H), 7.15 (dt, J = 7.4, 15.7 Hz, 1H), 6.50 (d, 
J = 15.9 Hz, 1H), 6.24 (dd, J = 8.7, 16.0 Hz, 1H), 5.93 (d, J = 15.7 Hz, 1H), 
3.72 (m, 1H), 2.48 (m, 3H), 1.17 (d, J = 6.8 Hz, 3H) ppm; 13C NMR (CDCl3, 
125 MHz) δ 170.88, 148.57, 140.52, 133.68, 130.98, 126.50, 126.45, 125.70 
(q, J = 3.8 Hz), 122.96, 73.91, 43.57, 37.60, 16.89 ppm; HRMS (ESI+) 




dienoic acid (74c). 84%; TLC Rf = 0.45 
(5:95 MeOH:DCM + 0.1% HOAc). 1H NMR (CDCl3, 500 MHz) δ 7.30 (d, J = 
8.7 Hz, 2H), 7.16 (dt, J = 7.3, 15.6 Hz, 1H), 6.85 (d, J = 8.7 Hz, 2H), 6.42 (d, 
J = 15.8 Hz, 1H), 5.95 (m, 2H), 3.81 (s, 3H), 3.65 (m, 1H), 2.51 (m, 1H), 2.38 
(m, 2H), 1.13 (d, J = 9.1 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz) δ 170.87, 
159.30, 148.70, 131.88, 129.83, 128.54, 127.51, 122.83, 114.15, 73.96, 
55.47, 43.62, 37.41, 17.00 ppm; HRMS (ESI+) 299.1260 m/z [M+Na]+ 













(74d). 73%; TLC Rf = 0.35 (5:95 MeOH:DCM 
+ 0.1% HOAc). 1H NMR (CDCl3, 500 MHz) δ 7.59 (d, J = 8.3 Hz, 2H), 7.44 (d, 
J = 8.4 Hz, 2H), 7.16 (dt, J = 7.3, 15.6 Hz, 1H), 6.48 (d, J = 15.9 Hz, 1H), 
6.31 (dd, J = 8.6, 16.0 Hz, 1H), 5.94 (d, J = 15.7 Hz, 1H), 3.75 (m, 1H), 2.47 
(m, 3H), 1.18 (d, J = 6.8 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz) δ 170.74, 
148.84, 141.57, 135.15, 132.60, 130.67, 126.93, 126.85, 122.81, 119.05, 
73.88, 43.61, 37.73, 16.90 ppm; HRMS (ESI+) 294.1102 m/z [M+Na]+ 
(C16H17NNaO3 requires 294.1106).  
 
6.4 MOSHER ESTER ANALYSIS 
!
Scheme 6.1: Synthesis of Mosher ester derivatives 103 and 105. Reaction conditions: (a) (S)-
MTPACl, pyridine, 60 oC, 24 h (103, 71%; 105, 70%).  
(R)-(3S,4R)-1-((tert-butyldimethylsilyl)oxy)-4-methylhex-5-en-3-yl 3,3,3-
trifluoro-2-methoxy-2-phenylpropanoate (103). A solution of 58 (6 mg, 
0.025 mmol) in anhydrous pyridine (50 μL) was treated with fresh (S)-(+)-α-
methoxy-α-trifluoromethylphenylacetyl chloride (S-MTPACl, 14 μL, 0.074 
mmol) and stirred at 60 oC under argon for 24 h. Reaction then cooled to 
room temperature, concentrated under vacuum, and purified by flash 


























0.90 (10:1 H:MTBE). 1H NMR (CDCl3, 500 MHz) δ 7.55 (m, 2H), 7.40 (m, 3H), 
5.67 (m, 1H), 5.24 (m, 1H), 5.05 (m, 2H), 3.61 (m, 2H), 3.54 (s, 3H), 2.54 (m, 
1H), 1.80 (m, 2H), 0.94 (d, J = 7.1 Hz, 3H), 0.88 (s, 9H), 0.02 (s, 6H) ppm; 
13C NMR (CDCl3, 125 MHz) δ 166.24, 138.60, 132.45, 129.68, 127.60, 
124.71, 122.42, 116.42, 77.30, 59.40, 55.53, 41.07, 33.89, 26.01, 18.37, 
15.37, -5.28 ppm; 19F NMR (CDCl3, 470 MHz) δ -71.19 (minor), -71.23 (major) 
ppm; HRMS (ESI+) 483.2159 m/z [M+Na]+ (C23H35F3NaO4Si requires 
483.2154). Compound 104 was prepared from 49 and (S)-(-)-57, the Mosher 
ester of which (105) was used for 19F NMR comparison purposes.  
Compound 104: 72%; TLC Rf = 0.45 (10:1 H:MTBE x2). 1H NMR (CDCl3, 400 
MHz) δ 5.80 (m, 1H), 5.04 (m, 2H), 3.83 (m, 2H), 3.68 (m, 1H), 3.36 (minor, d, 
J = 2.2 Hz), 3.21 (major, d, J = 2.2 Hz, 1H), 2.23 (m, 1H), 1.63 (m, 2H), 1.03 
(d, J = 6.9 Hz, 3H), 0.89 (s, 9H), 0.06 (s, 6H) ppm; 13C NMR (CDCl3, 100 MHz) 
δ 142.20, 110.32, 75.00, 65.65, 43.95, 35.53, 25.88, 18.16, 15.21, -5.51 ppm; 
HRMS (ESI+) 245.1935 m/z [M+H]+ (C13H29O2Si requires 245.1937). 
Compound 105: 70%; TLC Rf = 0.90 (10:1 H:MTBE). 1H NMR (CDCl3, 500 
MHz) δ 7.55 (m, 2H), 7.39 (m, 3H), 5.72 (m, 1H), 5.24 (m, 1H), 5.06 (m, 2H), 
3.54 (s, 3H), 3.50 (m, 2H), 2.57 (m, 1H), 1.74 (m, 2H), 1.03 (d, J = 7.0 Hz, 
3H), 0.87 (s, 9H), 0.01 (s, 6H) ppm; 13C NMR (CDCl3, 125 MHz) δ 166.30, 
138.85, 132.40, 129.69, 128.48, 127.63, 124.69, 122.40, 116.40, 77.37, 
59.20, 55.57, 41.27, 33.84, 26.00, 18.33, 15.62, -5.29 ppm; 19F NMR (CDCl3, 
470 MHz) δ -71.20 (major), -71.23 (minor) ppm; HRMS (ESI+) 483.2157 m/z 
[M+Na]+ (C23H35F3NaO4Si requires 483.2154). 
 
6.5 SYNTHESIS OF NOVEL SECO-CRYPTOPHYCIN SNAC-THIOESTER SUBSTRATES 
The SNAc-thioester CrpTE substrates were synthesized as previously 
reported with minor modifications as follows.3  
 
! 92!
 (S)-2-((tert-butoxycarbonyl)oxy)-4-methylpentanoic acid 
(76). The S-2-hydroxy-4-methylvaleric acid (1.0 g, 7.57 mmol) 
was flame-dried under vacuum and then suspended in 15 mL 
of anhydrous DMF. This suspension was treated with pyridine 
(3.06 mL, 37.85 mmol) and di-tert-butyl dicarbonate (3.48 mL, 15.13 mmol) 
and stirred at room temperature under argon overnight. The reaction was 
then acidified with 1.0 M HCl and diluted with water (100 mL) and EtOAc (100 
mL). The aqueous layer was extracted with additional EtOAc (2 x 50 mL) and 
the combined organics were washed with brine and dried with Na2SO4. 
Evaporation of the solvent and chromatographic purification (SiO2, 1:1:1 
H:E:CH2Cl2 + 0.1% HOAc) afforded the desired product (76, 462 mg, 27%) as 
a clear, light yellow oil. TLC Rf = 0.40 (2:1 H:E + 1% HOAc). 1H NMR (CDCl3, 
400 MHz) δ 4.90 (m, 1H), 1.85 (m, 2H), 1.66 (m, 1H), 1.47 (s, 9H), 0.95 (dd, J 
= 4.6, 6.1 Hz, 6H) ppm. 
 
 (S)-S-(2-acetamidoethyl) 2-((tert- 
butoxycarbonyl)oxy)-4-methylpentanethioate (77). 
A solution of 76 (2.06 g, 8.87 mmol) in CH2Cl2 (45 
mL) was treated with solid EDC•HCl (3.40 g, 17.74 
mmol), HOBt hydrate (2.72 g, 17.74 mmol), and DIPEA (3.40 mL, 19.51 
mmol). Reaction stirred at room temperature for 10 min and then treated with 
N-acetylcysteamine (SNAc, 1.70 mL, 15.96 mmol). After stirring at room 
temperature overnight, the reaction was diluted with CH2Cl2 (50 mL) and sat. 
aq. NaHCO3 (50 mL). The aqueous layer was extracted with additional 
CH2Cl2 (2 x 50 mL) and the combined organics were washed with 1.0 M HCl 
and brine, then dried with Na2SO4. Evaporation of the solvent and 
chromatographic purification (SiO2 + top CuSO4-impregnated SiO2 layer, 2:1 
CH2Cl2:E) afforded the desired product (77, 1.36 g, 46%) as a clear, colorless 











5.01 (dd, J = 3.9, 10.0 Hz, 1H), 3.42 (m, 2H), 3.06 (m, 2H), 2.03 (s, 3H), 1.78 





methylpropanoate (78). A solution of 77 
(392 mg, 0.943 mmol) in 4 N HCl/dioxane (2 mL) was stirred at room 
temperature for 2 h and then thoroughly dried under vacuum. The residue 
was dissolved in anhydrous THF (1.0 mL) and added to a stirred solution of 
(R)-3-(Boc-amino)-2-methylpropionic acid (230 mg, 1.13 mmol), EDC•HCl 
(217 mg, 1.13 mmol), HOBt hydrate (173 mg, 1.13 mmol), and DIPEA (360 
μL, 2.08 mmol) in 5.0 mL anhydrous THF. The reaction was stirred at room 
temperature overnight and then concentrated in vacuo. The reside was 
partitioned between dilute NH4Cl (50 mL) and CH2Cl2 (50 mL), and the 
aqueous layer was extracted with additional CH2Cl2 (2 x 50 mL). The 
combined organics were washed with brine and dried with Na2SO4. 
Evaporation of the solvent and chromatographic purification (SiO2, 3:97 
MeOH:CH2Cl2 to 5:95 MeOH:CH2Cl2) afforded the desired product (78, 126 
mg, 32% [51% brsm]) as a clear, colorless resin. TLC Rf = 0.65 (5:95 
MeOH:CH2Cl2 + 1% NH4OH). 1H NMR (CD3OD, 400 MHz) δ 8.13 (bs, 1H), 
6.69 (bs, 1H), 5.22 (dd, J = 3.8, 9.5 Hz, 1H), 3.22 (m, 2H), 3.01 (m, 2H), 1.92 
(s, 3H), 1.77 (m, 2H), 1.64 (m, 1H), 1.42 (s, 9H), 1.20 (d, J = 7.1 Hz, 3H), 













propanamido)-2-methylpropanoate (79). Compound 78 (621 mg, 1.48 
mmol) was dissolved in 4 N HCl/dioxane (7 mL) and stirred at room 
temperature for 30 min, then dried thoroughly under vacuum. The residue 
was dissolved in 5 mL anhydrous THF and added to a stirred solution of 87 
(1.66 mmol), EDC•HCl (339 mg, 1.77 mmol), HOBt hydrate (271 mg, 1.77 
mmol), and DIPEA (773 μL, 4.44 mmol) in 13 mL anhydrous THF. Reaction 
stirred at room temperature overnight and then concentrated under vacuum. 
The residue was partitioned between dilute NH4Cl (50 mL) and CH2Cl2 (50 
mL), and the aqueous layer was extracted with additional CH2Cl2 (2 x 50 mL). 
The combined organics were washed with brine and dried with Na2SO4. 
Evaporation of the solvent and chromatographic purification (SiO2, 3:97 
MeOH:CH2Cl2) afforded the desired product (79, 656 mg, 70%) as a white 
foam. TLC Rf = 0.70 (5:95 MeOH:CH2Cl2). 1H NMR (CD3OD, 400 MHz) δ 7.24 
(s, 1H), 7.12 (dd, J = 2.1, 8.4 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 5.22 (dd, J = 
3.9, 9.5 Hz, 1H), 4.19 (m, 1H), 3.84 (s, 3H), 3.49 (m, 1H), 3.27 (m, 2H), 3.00 
(m, 3H), 2.73 (m, 2H), 1.90 (s, 3H), 1.75 (m, 2H), 1.63 (m, 1H), 1.36 (s, 9H), 



















Compound 79 (130 mg, 0.206 mmol) was dissolved in 2 mL of 4 N 
HCl/dioxane and stirred at room temperature for 30 min, after which the 
reaction was thoroughly dried under vacuum. The residue was dissolved in 1 
mL anhydrous THF and added to a stirred solution of 48 (89 mg, 0.361 mmol), 
EDC•HCl (69 mg, 0.361 mmol), HOBt hydrate (55 mg, 0.361 mmol), and 
DIPEA (108 μL, 0.618 mmol). The reaction was stirred at room temperature 
overnight and then concentrated under a stream of nitrogen. The residue was 
partitioned between dilute NH4Cl (10 mL) and EtOAc (10 mL). The aqueous 
layer was extracted with additional EtOAc (2 x 10 mL) and the combined 
organics were washed with brine and dried with Na2SO4. Evaporation of the 
solvent and chromatographic purification (SiO2, 3:97 MeOH:CH2Cl2) afforded 
the desired product (80, 86 mg, 55%) as a clear, faint yellow oil. TLC Rf = 
0.55 (5:95 MeOH:CH2Cl2). Compounds 81, 82, and 83 were accessed in an 
analogous manner. Compound 80: 1H NMR (CD3OD, 500 MHz) δ 7.36 (d, J = 
7.6 Hz, 2H), 7.26 (m, 3H), 7.14 (m, 2H), 6.96 (d, J = 6.8 Hz, 1H), 6.80 (dd, J = 
7.6, 15.2 Hz, 1H), 6.41 (d, J = 15.9 Hz, 1H), 6.23 (dd, J = 8.6, 15.9 Hz, 1H), 
6.00 (d, J = 15.4 Hz, 1H), 5.21 (m, 1H), 4.56 (m, 1H), 3.83 (s, 3H), 3.64 (m, 
1H), 3.48 (dd, J = 6.5, 13.4 Hz, 1H), 3.18 (dd, J = 7.0, 13.5 Hz, 1H), 3.01 (m, 
3H), 2.83 (m, 1H), 2.68 (m, 1H), 2.40-2.30 (m, 3H), 1.74 (m, 2H), 1.62 (m, 
1H), 1.14 (d, J = 6.9 Hz, 3H), 1.09 (d, J = 7.1 Hz, 3H), 0.93 (dd, J = 5.2, 11.6 















153.96, 142.08, 137.61, 131.05, 130.67, 130.47, 130.05, 128.41, 128.05, 
126.61, 125.70, 124.64, 111.90, 77.19, 73.90, 55.13, 54.82, 42.79, 41.29, 
40.52, 39.14, 38.42, 37.40, 37.38, 36.64, 27.13, 24.31, 22.05, 21.10, 20.52, 






47%; TLC Rf = 0.35 (5:95 MeOH:CH2Cl2). 1H NMR (CD3OD, 500 MHz) δ 8.43 
(m, 1H), 7.76 (m, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.23 (m, 2H), 7.13 (dd, J = 2.2, 
8.4 Hz, 1H), 6.96 (d, J = 8.5 Hz, 1H), 6.80 (m, 1H), 6.66 (dd, J = 8.4, 16.0 Hz, 
1H), 6.51 (d, J = 16.0 Hz, 1H), 6.02 (d, J = 15.4 Hz, 1H), 5.20 (m, 1H), 4.58 
(m, 1H), 3.82 (s, 3H), 3.67 (m, 1H), 3.48 (dd, J = 6.6, 13.5 Hz, 1H), 3.19 (dd, 
J = 7.1, 13.5 Hz, 1H), 3.01 (m, 3H), 2.84 (m, 1H), 2.69 (m, 1H), 2.47-2.32 (m, 
3H), 1.90 (s, 3H), 1.73 (m, 2H), 1.62 (m, 1H), 1.17 (d, J = 6.9 Hz, 3H), 1.09 (d, 
J = 7.1 Hz, 3H), 0.92 (dd, J = 6.4, 14.2 Hz, 6H) ppm. 13C NMR (CD3OD, 125 
MHz) δ 198.91, 173.64, 172.06, 171.99, 166.60, 155.83, 153.97, 148.26, 
141.86, 137.31, 137.21, 130.48, 128.43, 124.83, 120.90, 111.92, 77.20, 
73.67, 55.15, 54.82, 42.65, 41.31, 40.53, 39.14, 38.43, 37.34, 36.67, 29.25, 



























methylpropanoate (83). J. Schmidt  
 
 (R)-methyl 2-((tert-butoxycarbonyl)amino)-3-(3-
chloro-4-hydroxyphenyl)propanoate (85). A 
suspension of H-D-Tyr-OMe!HCl (84, 10.0 g, 43.16 
mmol) in glacial acetic acid (86 mL) was stirred 
vigorously and cooled to 0 °C in an ice bath. Sulfuryl 
chloride (4.2 mL 51.79 mmol) was then added dropwise and reaction stirred 
while warming to room temperature over 1 h. The reaction was then diluted 
with Et2O (86 mL) and stirred for an additional 30 min at room temperature. 












































dried under vacuum, and suspended with NaHCO3 (750 mg, 8.93 mmol) in 28 
mL of a 4:1 mixture of THF and MeOH. This suspension was next treated with 
(Boc)2O (1.07 mL, 4.67 mmol) and stirred at room temperature for 4 h. The 
reaction was then concentrated and partitioned between 1.0 M HCl (50 mL) 
and CH2Cl2 (50 mL). The aqueous layer was extracted with additional CH2Cl2 
(2 x 50 mL) and combined organics washed with brine (100 mL) and dried 
with Na2SO4. Purification completed by J. Schmidt for an 89% yield over 2 




Compound 85 was suspended with K2CO3 (1.29 g, 9.35 
mmol) and iodomethane (582 μL, 9.35 mmol) in 22 mL 
of acetone dried over Na2SO4 and stirred at reflux 
temperature for 2 h. The reaction was then cooled to room temperature and 
concentrated under vacuum. The residue was partitioned between CH2Cl2 (50 
mL) and dilute NH4Cl (50 mL), and the aqueous layer was extracted with 
additional CH2Cl2 (2 x 50 mL). The combined organics were washed with 
brine (100 mL) and dried with Na2SO4. Evaporation of the solvent and 
chromatographic purification (SiO2, 2:1 H:E) afforded the desired product (86, 
1.30 g, 89%) as a clear, colorless oil. TLC Rf = 0.90 (1:1 H:E). 1H NMR 
(CDCl3, 500 MHz) δ 7.12 (s, 1H), 6.98 (d, J = 8.4 Hz, 1H), 6.84 (d, J = 8.0 Hz, 
1H), 4.99 (m, 1H), 4.52 (m, 1H), 3.87 (s, 3H), 3.71 (s, 3H), 2.99 (dt, J = 5.5, 
14.0 Hz, 2H), 1.42 (s, 9H) ppm. 
 
 (R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-
methoxyphenyl)propanoic acid (87). A solution of 86 
(570 mg, 1.66 mmol) in 8 mL of a 4:1 mixture of THF 












3.32 mmol) and stirred at room temperature for 1 h. The reaction was judged 
to be complete after 1 h by TLC and then concentrated under vacuum. The 
resulting residue was partitioned between water and CH2Cl2, with the 
aqueous layer adjusted to pH ~3 with HCl. The aqueous layer was then 
extracted with additional CH2Cl2 and the combined organics were washed 
with brine and dried with Na2SO4. The solvent was evaporated under vacuum 
and the resulting residue used for coupling without further purification.  
 
Cryptophycin 500. A 20 mL SPE 
tube equipped with a bottom frit 
was charged with 2.834 mL of 100 
mM sodium phosphate buffer, pH 
6.5, 925 μL diglyme, 166 μL of 30% 
aqueous methyl β-cyclodextrin, and 75 μL of 81 (50 mM in DMSO). CrpTE 
was then thawed on ice, 1 mL of purified protein was added to the SPE tube, 
and the tubes were tightly capped. The reaction was mixed by gently swirling 
the tube and then incubated at room temperature overnight on a rotary 
agitated set to 250 rpm. After overnight incubation, an equal volume with 
EtOAc was added to the tube and the reaction was shaken vigorously. The 
two-phase mixture was filtered though a packed column of celite - washing 
with water and EtOAc - transferred to a separatory funnel, and the aqueous 
layer was extracted with additional EtOAc (2 x 50 mL). The combined organic 
layers were washed with brine and dried with Na2SO4. Evaporation of the 
solvent and chromatographic purification (SiO2, 3:97 MeOH:CH2Cl2) afforded 
the desired product (Crp 500, 3.4 mg, 35%) as a clear, colorless oil. TLC Rf = 
0.55 (5:95 MeOH:CH2Cl2). Cryptophycin 500: 1H NMR (CD3OD, 400 MHz) δ 
8.44 (dd, J = 5.0, 8.1 Hz, 1H), 7.76 (dt, J = 1.7, 7.6 Hz, 2H), 7.47 (d, J = 7.8 
Hz, 1H), 7.24 (m, 2H), 7.15 (dd, J = 2.2, 8.5 Hz, 1H), 6.96 (d, J = 8.5 Hz, 1H), 
6.69 (ddd, J = 3.9, 11.1, 15.0 Hz, 1H), 6.56 (m, 2H), 5.90 (d, J = 15.1 Hz, 1H), 













11.2 Hz, 1H), 3.82 (s, 3H), 3.57 (m, 2H), 3.32 (s, 3H), 3.24 (m, 1H), 3.16 (dd, 
J = 3.7, 14.6 Hz, 1H), 2.69 (m, 4H), 2.37 (m, 2H), 2.19 (m, 2H), 2.01 (m, 1H), 
1.58 (m, 4H), 1.17 (s, 3H), 1.15 (s, 3H), 0.87 (d, J = 7.2 Hz, 3H), 0.70 (dd, J = 
6.4, 14.3 Hz, 6H) ppm. 13C NMR (CD3OD, 100 MHz) δ 196.1, 179.3, 176.1, 
172.6, 170.8, 166.9, 166.7, 155.1, 153.9, 148.5, 142.0, 139.6, 137.3, 136.2, 
130.7, 130.6, 130.0, 127.8, 124.1, 122.3, 121.8, 121.4, 112.0, 77.0, 76.7, 
71.4, 55.9, 55.1, 54.8, 42.0, 39.4, 37.5, 36.4, 34.9, 31.6, 29.3, 29.0, 24.2, 
21.8, 20.2, 16.1, 13.6 ppm. HRMS (ESI+) 640.2971 m/z [M+H]+ 
(C34H43ClN3O7 requires 640.2790).  
 
6.6 SYNTHESIS OF METHYLATED CrpTE SUBSTRATE 
 The successful capture of a CrpTE crystal structure was not successful 
using wild type enzyme, so a substrate hindered in its ability to undergo 
cyclization was prepared as described in Scheme 6.2. When substrate 102  
!
Scheme 6.2: Preparation of a methylated CrpTE substrate blocked in cyclization. Reaction 
conditions: (a) Ag2O, MeI, THF, 23 oC, 24 h; (b) LiOH, MeOH/THF/H2O, 23 oC; then EDC, HOBt, 




























Figure 6.1: LC-QTOF-MS analysis of CrpTE acylation with methylated unit A substrate. Reaction 
conditions: 30 uM CrpTE, 50 uM 102, 50 mM sodium phosphate, pH 7.0, 5% DMSO, 23 °C, 4 h. Top 
panel is MS trace of CrpTE with analyzed inset; bottom panel is extracted spectrum of inset showing 
WT CrpTE and acylated CrpTE. 
was incubated with CrpTE at room temperature over 4 h, only a trace amount 
of the acyl-CrpTE complex was observed by LC-QTOF-MS (Figure 6.1). 
Clearly hydrolysis of the substrate dominated when cyclization was blocked, 
but we were encouraged by the observation that CrpTE could still accept 
substrates disfavoring catalytic turnover. 
!
6.7 CrpTE EXPRESSION, PURIFICATION, AND ENZYMATIC REACTION 
 The expression and purification of CrpTE was carried out as previously 
reported by Beck et al. as the pET28b construct in E. coli strain BL21 (DE3).4 
One liter cultures of 2XYT media containing 50 μg/mL kanamycin were 
inoculated with 1% (v/v) of an LB starter culture and grown to OD600 of 0.6-0.8 
at 37 °C and 160 rpm. Overexpression was induced by the addition of 100 μM 
IPTG at 30 °C for approximately 16 h. CrpTE was purified on Ni agarose resin 
to >95% purity. Purified protein aliquots were stored in 100 mM sodium 
phosphate buffer, pH 7.8, snap frozen in liquid nitrogen, and stored at -80 °C 
until needed. 
 Small-scale CrpTE reactions were conducted in 1.7 mL Eppendorf 
tubes containing 100 μM purified CrpTE, 500 μM substrate (at 50 mM in 
DMSO), 5% (v/v) DMSO, and 50 mM sodium phosphate buffer, pH 7.0 in 100 
102 
! 102!
μL total volume. Reaction components were combined, adding CrpTE last, 
then shaken by inversion, briefly centrifuged to settle the contents, and 
incubated at 28 °C overnight. After incubation, reactions were extracted with 
EtOAc (2 x 200 μL) and the organics were combined in a clean 1.7 mL 
Eppendorf tube and dried under a stream of nitrogen. The residue was 
resuspended in LC-MS grade ACN and briefly centrifuged for analysis by LC-
QTOF-MS using a Phenomenex Synergi 4u HydroRP (100 x 2.0 mm, 4 μm) 
column under the following conditions: mobile phase (A) deionized water + 
0.1% formic acid (FA), (B) acetonitrile + 0.1% FA; 0-2 min 10% B, 2-17 min 
10-100% B, 17-18 min 100% B, 18-19 min 100-10% B; flow rate, 0.3 mL/min.  
 For large-scale reactions, it is recommended to charge 20 mL SPE 
tubes equipped with a bottom frit with 500-750 μM SNAc-thioester substrate, 
20% (v/v) diglyme, 1% methyl β-cyclodextrin, 1 mL purified CrpTE, and 
enough 100 mM sodium phosphate buffer, pH 7.0 to make 5 mL total volume. 
The SPE tubes are then capped and agitated in an upright position on an 
orbital shaker at 250 rpm at room temperature. After 16 h, reactions are 
diluted with EtOAc (10 mL), shaken vigorously, and filtered through a 
compressed plug of celite. The filtrate is then transferred to a separatory 
funnel and diluted with water and EtOAc. The organic layer is washed with 
brine and then dried with Na2SO4, after which solvent removal under vacuum 
provides a residue for purification.  
  Compound 88 was acquired from W. Seufert and analyzed by 1H NMR 
and HRMS to confirm identity and purity.  
 
6.8 CrpE EXPRESSION, PURIFICATION, AND ENZYMATIC REACTION 
 Soluble, active CrpE was grown in E. coli BL21 (DE3) containing the 
CrpE gene on a pSJ8 plasmid and the pGro7 chaperone plasmid. One liter 
TB cultures containing 50 μg/mL ampicillin and 25 μg/mL chloramphenicol 
were seeded with 1% (v/v) LB starter cultures and supplemented with 0.5 mM 
Fe(NH4)2(SO4)2 and 1 mM thiamine. Cells were grown to an OD600 of 0.6 at 
! 103!
37 °C, 160 rpm, supplied 2 mM 5-ALA, and acclimated to 18 °C over 1 h. 
Cultures were then induced with 1.0 g/L arabinose and 100 μM IPTG, and 
incubated at 18 °C, 160 rpm for 18 h. The resulting cell pellet was lysed by 
sonication and soluble protein was purified on amylose resin to afford CrpE at 
14 μM with the GroEL chaperone (Figure 6.1). The functional concentration of 
CrpE was measured by diluting 500 μL of purified enzyme with 2.5 mL water 
and sparging with CO for 30 sec. The UV-Vis spectrum of 800 μL of the 
diluted CrpE in a cuvette was then recorded from 380 to 550 nm, followed by 
the addition of ~10 mg of sodium dithionite. A series of UV-Vis measurements 
were then recorded over 5 min to catch the transition to 450 nm.  
!
Figure 6.2: Purification and Functional Analysis of CrpE. A) SDS-PAGE gel of CrpE purification. 
Lane 1, Invitrogen Benchmark™ protein ladder; lane 2, whole cell protein after induction; lane 3, 
insoluble lysate pellet; lane 4, lysate soluble fraction; lane 5, resin flow-through; lane 6, purified MBP-
CrpE (red) and GroEL (green); lane 7, Invitrogen Benchmark™ protein ladder. B) CO binding assay of 
CrpE functionality observing the shift from 420 to 450 nm upon reduction of the heme.  
 A typical CrpE reaction in a 1.7 mL Eppendorf tube contained 100 
μg/mL spinach ferredoxin, 0.2 unit/mL ferredoxin reductase, 1.4 mM NADPH, 
10 mM glucose-6-phosphate, 8 units/mL glucose-6-phosphate 
dehydrogenase, 5 μM substrate (in DMSO), and 5% (v/v) DMSO in 100 μL of 
50 mM sodium phosphate, pH 6.4. Reaction components were mixed by 





























then added last to a final concentration of 0.2 μM. Reactions were incubated 
for 4 h at room temperature and then extracted with EtOAc (2 x 200 μL). The 
combined organics were transferred to a clean Eppendorf tube and dried 
under a stream of nitrogen. The resulting residue was dissolved in LC-MS 
grade ACN and briefly centrifuged for analysis by LC-QTOF-MS using a 
Phenomenex Synergi 4u HydroRP (100 x 2.0 mm, 4 μm) column under the 
following conditions: mobile phase (A) deionized water + 0.1% formic acid 
(FA), (B) acetonitrile + 0.1% FA; 0-2 min 10% B, 2-17 min 10-100% B, 17-18 
min 100% B, 18-19 min 100-10% B; flow rate, 0.3 mL/min 
 Cryptophycin 4 was obtained from W. Seufert and analyzed by 1H NMR 
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1H, 13C, and 19F NMR Spectra of All New Compounds 
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13C NMR Spectrum of Cryptophycin 500 
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